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                      ABSTRACT              
The effect of macrolides on allergic rhinitis  versus 
chronic rhinosinusitis- An in-vitro study.  
 Background 
The mechanisms of the rhinitic process are complex. Previous studies upon nasal 
epithelial cells have begun to investigate rhinitis. HNECs from turbinate explant 
tissue were taken from three patient groups (Normals, Chronic Rhinosinusitics and 
Rhinitics). 
Aims 
The study, firstly, aims to establish fundamental differences in cytokine activity  
 
between  allergic rhinitis and chronic rhinosinusitis by analysing baseline levels  
 
of cytokines IL-6 and IL-8 and subsequent impact of bacterial endotoxin.  
 
Secondly the study analyses the affect of macrolides on activity in each sub-  
 
group. 
 
 
Methods 
 
HNECs were grown from the biopsy specimens as explant culture. Standardised  
 
exposures to LPS bacterial endotoxin and  macrolide were carried out. The  
 
concentration of each mediator present in the medium at the end of incubation  
 
was assessed by ELISA). A final quantity of total cellular protein was obtained. 
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Results 
 
Baseline levels of IL-6 in unstimulated Allergic Rhinitics are  
 
significantly higher than in Normal patients. Baseline levels of IL-8, however, are 
lowest in Allergics. LPS significantly stimulates Allergics to increase production 
of both IL-6 and IL-8. Macrolides lower IL-6 and IL-8 in both stimulated and 
unstimulated AR cells.  
Baseline levels of IL-6 and IL-8 are higher in CRS than AR and Normals. LPS 
significantly raises IL-6 and IL-8 in CRS. Macrolides increase IL-6 and IL-8 in 
stimulated CRS cells however reduce levels of both in un-stimulated cells.  
         Discussion 
Pre-existing neutrophilic and eosinophilic activity in CRS subjects may explain the 
increased baseline levels of both cytokines upon macrolide exposure. 
Whilst some studies have suggested macrolides act as antimicrobial, others have 
suggested that it is their anti-inflammatory effects that are more relevant. 
Treatment for Allergic Rhinitis needs to be effective long-term. The results here 
are novel and encourage further research to improve understanding of the effects of 
macrolides in a potentially pivotal role. 
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7.1  NASAL ANATOMY AND PHYSIOLOGY                                              
The healthy adult, the nose is a vital organ in the respiratory pathway, acting as not 
only an air- conditioner for warming and saturating inspired air but also acting as a 
filter by removing particulate debris and infectious agents. It thereby allows 
conservation of heat and moisture from expired air. It is known that we breathe 
10,000 to 20,000 litres of air per day, the majority of which passes through the 
nose. 
7.1.1 Embryology 
The development of the nose begins in the third intrauterine week. By the fourth 
week, paired depressions termed olfactory placodes become visible in the cranial 
ectoderm above the stomatodeum. The mesoderm around these olfactory placodes 
thickens to form the medial and lateral nasal folds. The nasal placodes deepen 
further to form nasal pits and then subsequently nasal sacs by the fifth week. The 
medial nasal folds fuse to become the upper lip, premaxilla and primitive nasal 
septum. With growth of the maxillary process of the first branchial arch and the 
mesoderm of the frontonasal process, the primitive palate is formed. The nasal sacs 
deepen and thin the bucconasal membrane until it ruptures to form the posterior 
choanae. 
The nasal septum continues to form from contributions made by the frontonasal 
process and the forebrain capsule. The union of the palatal processes of the 
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maxillary processes form the nasal capsule, in mesoderm. Chondrification and 
subsequent ossification occurs.  
 
7.1.2 Gross Anatomy 
The nose is composed of a cartilaginous and bony framework. The basic structure 
consists of a floor, a roof and 2 lateral walls. The floor of the nose is formed by the 
hard palate with the cavity extending posteriorly to the soft palate. Here the 
choanae open into the nasopharynx. Anteriorly the roof of the nose is formed by 
the cranial fossa and contains the cribriform plate, a thin lamina of bone perforated 
by olfactory nerve fibres. The roof of the sphenoid arches downwards to form the 
superior  aspect of the nasopharynx. The bony structure of the nose comprises of 
paired bones which meet in the midline to form a bony pyramid with the base of 
the pyramid being formed by the frontal process of the maxilla. The lower two 
thirds of the external framework of the nose are formed by the paired upper and 
lower lateral cartilages and intervening sesamoid cartilages. 
The nasal septum divides the internal structure of the nose. This is again an osseo-
cartilaginous structure. It is comprised mainly of the septal cartilage which has a 
free anterior border but articulates postero-superiorly with the perpendicular plate 
of the ethmoid, postero-inferiorly with the vomer and inferiorly with the maxillary 
crest. It receives additional contributions from the palatine bone and the anterior 
spine of the maxillary crest. 
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The nasal vestibule begins at the nasal alae and is bounded internally by the region 
of the nasal valve. This area has short thick hairs (vibrissae) that aid in filtration of 
gross particulate matter. The nasal valve region is formed by the junction of the 
upper lateral cartilages, the nasal septum and the inferior turbinate. As this area 
accounts for some 50% in airway resistance, changes in cross-sectional area at this 
site can contribute significantly to total airway resistance. Area changes at this site 
are dependent upon the tone of the nasal vestibule. The tone in this region is 
mediated by the dilator alae muscles i.e. dilator nasae and dilator aleque nasae. 
This is under neurogenic control facilitated by branches of the facial nerve and an 
increase in tone of these muscles (flaring of the nostrils) results in an increase in 
cross-sectional area and a concomitant decrease in airway resistance. However, an 
increased negative pressure in this region, such as during increased respiratory 
effort, can have an opposite effect by causing the nasal vestibule to collapse 
inwards and decrease cross-sectional area. 
The lateral wall of the nasal cavity passes superiorly to meet the nasal septum and 
cribriform plate. It has three elongated processes, the nasal turbinates, which are 
scroll-shaped bony structures covered by highly vascular mucosa. Such vascularity 
enables these turbinates to change in size to facilitate their role in the physiological 
functions of the nose. Beneath each of these turbinates lie corresponding openings 
(ostia). The inferior ostium receives the naso-lacrimal duct, the superior ostium 
receives the drainage of the sphenoid and posterior ethmoid sinuses with the 
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middle meatus which is a complex of openings receiving the drainage of the 
remaining nasal sinus. 
 
 
Fig.1 
 
 
(Courtesy of www.blumdesign.com, Jan 2008) 
 
7.1.3 Nasal Histology 
The nasal cavity is lined by 3 types of epithelium: (Eccles, 1996) 
1) Stratified squamous epithelium in the nasal vestibule and nasopharynx. 
2) Pseudostratified ciliated columnar epithelium within the main respiratory 
area of nasal cavity and paranasal sinuses. 
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3) Specialised olfactory epithelium with ciliated receptor cells in the roof of the 
nose. 
The nose lies at the junction of the upper respiratory tract with the external 
stratified squamous epithelium of skin and thus has a brief transitional zone i.e. the 
nasal vestibular area is lined by stratified squamous hair bearing skin but beyond 
this the mucosa is transitional and then only becomes the typical respiratory 
pseudostratified ciliated columnar epithelium . Indeed, while the mucosa of the 
inferior turbinate is entirely ciliated at birth, it is thought that as a result of airflow 
over its anterior extremity, its ciliated character is lost at this site. 
Additionally, conforming to its role in olfaction, the area at the roof of the nasal 
cavity in the region of the cribriform plate contains a concentration of special 
olfactory cells. These cells also extend from here to the epithelium of the superior 
turbinate. 
Fig.2                               Nasal Epithelium 
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Courtesy of www.cellbio.utmb.edu, Jan 2008 
 
Fig.3 
 
Courtesy of www.science.blogdig.net, Jan 2008 
 
7.1.4 Nasal Cytology 
The nasal epithelium has within it four cell types- namely basal, goblet, columnar 
and inflammatory cells. 
Columnar cells account for the pseudostratified nature of respiratory epithelium as 
they are all anchored to the basement membrane. Their surface area is increased by 
microvilli which also help to prevent drying of the epithelium. Beyond the nasal 
vestibule and tip of the inferior turbinate, most columnar cells are also ciliated. The 
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breakdown of adenosine tri-phosphate (ATP) in the nine anterior micro tubules 
provides the energy for ciliary movement (Brain, 1989). Cilia provide an efficient 
transport of nasal mucus with co-ordinated rhythmical activity. Human and animal 
studies suggest that mucociliary clearance is influenced by the autonomic nervous 
system. Recent work seems to suggest that human nasal epithelium does play an 
immunomodulatory role in the upper airway by synthesis and thereby release of 
specific biochemicals, including pro-inflammatory cytokines and cell adhesion 
molecules. 
In those with an enhanced inflammatory response e.g. allergic rhinitics, cells 
including eosinophils and mast cells proportionately increase. A ground substance 
and tissue fluid contain loose connective tissue, submucosal glands, vasculature 
and extra-vasculature immunocytes. This ground substance is a gel composed of 
water, electrolytes and serum proteins. 
 
 
 
 
 
 
 
 
  24 
 
Fig.4     Nasal epithelium goblet cells and cilia 
 
Courtesy of www.cellbio.utmb.edu, Jan 2008 
 
7.1.5 Nasal Glands 
These types of glands can be found in the epithelium and submucosa of the nose: 
anterior serous glands, seromucous glands and intra-epithelial glands. 
Tos deduced that anterior serous glands were few with 20-30 located on the septum 
and equal number on the lateral wall and were thereby their total secretion was 
minimal. 
Seromucous glands lie deep within the lamina propria. Vessels, nerves and fibres 
form within them. The glands are thought to total more than 90,000. 
Intraepithelial glands are located within the epithelium. They produce a small 
amount of mucus in relation to seromucous glands. 
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7.1.6 Nasal Vasculature and Lymphatics 
The nasal submucosa is a very vascular layer. 
The nose receives blood supply from both the internal via the ophthalmic artery 
which gives rise to the anterior and posterior ethmoid arteries. They supply the 
anterosuperior portion of the septum, the lateral nasal walls, the olfactory region 
and a small part of the posterosuperior region. The external carotid arteries supply 
the nose via the internal maxillary arteries which enters the nasal cavity through 
the sphenopalatine foramen just behind the posterior end of the middle turbinate. 
The sphenopalatine artery gives rise to posterior lateral and septal branches. These 
branches are the majority of the blood supply to the nose including the floor. 
The venous supply accompanies the corresponding arteries and drains into the  
pterygoid plexus. This system also drains the ophthalmic plexus in the orbit and 
most importantly are part of the system draining into the cavernous sinus. There is 
a large anastomotic system within the veins of the face, palate and pharynx. It must 
be remembered that the system is a valveless one, thereby predisposing to the 
spread of infection. 
Lymphatic system of the nose drains from the vestibule to the external nose 
however endonasally drainage leads posteriorly.  
7.1.7 Submucosal immunocytes 
Immunocytes are characteristically found in the nasal submucosa include 
eosinophils, T and B lymphocytes, mast cells, neutrophils, basophils and plasma 
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cells.  
7.1.8 Nasal Nerve Supply 
The nasal cavity is supplied by the nerve to the first branchial arch namely the 
trigeminal nerve. Fibres from the ophthalmic and maxillary branches of the 
trigeminal nerve provide tactile and sensory relays but also provide secretomotor 
fibres. Sympathetic innervation is provided by the superficial petrosal nerve and 
sympathetic nerve supply is provided by the deep petrosal nerve. These two nerves 
together form the nerve of the pterygoid canal (Vidian nerve). 
 
7.1.9 Nasal Secretions 
Nasal secretions enable an effective defense mechanism between a delicate 
respiratory mucosa and dry, polluted, cold air. The nose and paranasal sinuses 
produce approximately 1litre of secretions each day. The two main constituents are 
a superficial gel and a deep periciliary layer.  
7.1.10 Nasal Physiology 
The nose whilst superficially being important in facial cosmesis, has several 
physiological roles. Namely- 
1. Its functions as part of the gateway to the upper respiratory tract i.e. 
a. Provision of airway resistance with the nasal valve region contributing 
to 50% of airway resistance 
b. Humidification of air 
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c. Warming of air 
d. Filtration of air 
e. Guardian to foreign matter; both mechanical e.g. by vibrissae and 
mucous and immunological 
2. Olfaction (and its associated contribution to the sensation flavour) 
3. Together with the paranasal sinuses, enhancement of the timbre of voice. 
7.2 NASAL INFLAMMATION 
The term ‘rhinitis’ implies inflammation. The symptoms include sneezing, 
irritation, anterior discharge, hyposmia, anosmia and nasal obstruction. Secondary 
symptoms include headache, facial pain, ear popping, nasal obstruction, dry throat, 
post-nasal drip, cough and eye symptoms. It is estimated that morbidity associated 
with nasal symptoms is responsible for over £1.5million caused by loss of working 
hours.  
The pathophysiology of rhinitis, allergic and non-allergic, is yet to be fully 
understood. The classification of rhinitis is evolving. Allergic rhinitis whether, 
seasonal, perennial or episodic is easier to define, investigate and manage. Non-
allergic rhinitis, however is a more difficult entity with a more aetiological basis of 
diagnosis. For the purposes of this thesis we focus on skin prick test positive 
allergic rhinitis and chronic rhinosinusitis confirmed by a pre- operative CT-scan, 
the criteria of which I will explain in further detail later.  
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7.2.1 Nasal Allergy 
The nasal allergic response consists of two responses that overlap; a mast cell 
mediated immediate hypersensitivity reaction and a late phase response. The 
immediate response is seen classically in allergic rhinitis within 2-5 minutes of 
allergen exposure and reaches a peak after approximately 15 minutes. The late 
phase response occurs approximately 4-6 hours later and takes place under the 
influence of a vast number of inflammatory mediators such as cytokines released 
from nasal epithelial cells and immunocytes.                                                 
 
7.2.2  The immediate hypersensitivity response  
Pathophysiology 
 
The immediate response is a Gell & Coombs Type I response, mediated  
 
by mast cell degranulation. Cross-linking of mast cells with immunoglobulin E  
 
(IgE), triggers the process. An influx of intracellular calcium and exocytosis of  
 
granule content (Bousquet et al, 1996) is stimulated. A specific antigen usually will  
 
then cause cross-linking however mast cells can be  triggered by other stimuli e.g 
 
cytokines, neuropeptides, complement. 
 
 
7.2.3 IgE 
 
IgE production occurs locally at mucosal surfaces, when an allergen  
 
enters the body. The allergen interacts interacts with mucosal antigen  
 
presenting cells, which capture, process and present antigen to T- helper 
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cells, which capture, process and present the antigen to T helper  
 
lymphocytes. These T lymphocytes become activated and via interleukin-  
 
4(IL-4), IL-6 and IL- 13 signalling, cause B lymphocytes to preferentially  
 
produce IgE (Vercelli & Geha, 1993). 
 
IgE is locally produced and first attaches to local immunocytes, but  
 
excess  IgE enters the systemic circulation and binds to both circulating  
 
basophils and tissue fixed mast cells throughout the body. The normal  
 
function is IgE is as defence against parasitic  infection, however the  
 
characteristic feature of atopy is inappropriate preferential production of  
 
IgE in response to antigenic stimulation by common aero-allergens. 
 
 
7.2.4 Mast cells 
 
Mast cells are superficially located in the respiratory epithelium and are  
 
ideally placed to respond to inspired antigens. The immunological  
 
staining of mast cells in nasal biopsies shows an increase in the number of  these  
 
cells within the nasal epithelium in both perennial and seasonal rhinitis  
 
compared with non- atopic, non- rhinitic individuals (Bentley et al, 1992;  
 
Bradding et al, 1993). 
 
7.2.5 Mast cell derived inflammatory mediators 
 
Mast cell granules contain pre-formed mediators including histamine,  
 
heparin and proteolytics enzymes. These are responsible for the classic 
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nasal symptoms seen in the immediate hypersensitivity response- itch, 
 
sneeze, discharge and blockage- through interaction with receptors  
 
present on both neural and vascular elements within the nasal mucosa.  
 
Other pre-formed mediators include eosinophil chemotactic factor,  
 
neutrophil chemotactic membrane occurs to produce de novo synthesis of  
 
inflammatory mediators, such as leukotrienes, prostaglandins and platelet  
 
activating factors (Lee, Naclerio et al. 1994). 
 
 
7.2.6 Mast cell pro-inflammatory Cytokines 
 
Nasal mast cells also contain pre-formed cytokines, including IL-4, IL-5,  
 
IL-6 and Tumour necrosis factor-α (TNFα) which contribute to the  
 
immunocyte growth, differentiation, adhesion and activation seen in the  
 
late phase response  (Bradding, Feather et al. 1993; Bradding, Okayama et al.  
 
1995).  
 
 
7.2.7 The late phase response 
 
The immediate hypersensitivity response does not entirely explain the  
 
symptomatology of patients with allergic rhinitis. The following  
 
observations support this notion: 
 
1) The duration of the early reaction to antigen is measured in  
 
     minutes, whereas clinical disease is more prolonged, with patients  
 
complaining of symptoms hours after allergen exposure. 
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2) Biopsies of atopic nasal mucosa during the allergy season show an 
 
 inflammatory cellular infiltrate, whereas studies of acute  
 
hypersensitivity reaction show only mast cell degranulation and  
 
tissues oedema. 
 
3) Systemic steroids, although useful in refractory cases of allergic  
 
rhinitis, do not inhibit the early reaction. 
 
 
The late phase response- Definition 
 
The nasal phase response is defined as a recurrence of symptoms and the  
 
appearance of inflammatory mediators in nasal secretions 3-11  hours  
 
after allergen exposure. (Naclerio, 1999). 
 
 
7.2.8 Pathophysiology 
 
A significant increase occurs in the number of immunocytes in the nasal  
 
lining, including basophils, eosinophils, T-helper lymphocytes,  
 
neutrophils and mononuclear cells (Okuda, Sakaguchi et al. 1983; Okuda, Ohtsuka  
 
et al. 1985; Bascom, Wachs et al. 1988; Howarth 1995) .  
 
This response usually occurs within a few hours after the early  
 
response. This cellular influx is mediated by cytokines such as IL-1β,  
 
TNFα, IL-3, IL-5, IL-8, “released on activation, normal T cell expressed  
 
and secreted” (RANTES), granulocyte-macrophage colony stimulating  
 
factor (GM-CSF) and adhesion molecules such as intercellular adhesion 
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molecule-1 (ICAM-1) (Ciprandi, Pronzato et al. 1994), vascular intercellular  
 
adhesion molecule-1 (VCAM-1), selectins and integrins  (Bachert, Hauser et al.  
 
1995). 
 
7.2.9 Cellular infiltration- T lymphocytes 
 
In contrast to the immediate hypersensitivity response, much of the nasal  
 
late phase response is thought to be under the control of pro-inflammatory  
 
cytokines. The two principal mucosal sources for the cytokines are nasal  
 
respiratory epithelium and T helper lymphocytes.  These lymphocytes  
 
have been classified into subsets Th1 and Th2 on the basis of their  
 
distinct cytokine profile. Th2 clones predominate in allergic rhinitis and  
 
secrete TNFα, IL-3, IL-4, IL-5, IL-6, IL-10, IL13 GMCSF. Th2 clones 
 
are more effective than Th1 at assisting nasal IgE production. 
 
7.2.10 Nasal epithelial cell derived inflammatory mediators 
 
Nasal epithelial cells hold two distinct roles in the inflammatory  
 
response. They enable clearance of particulate matter from the airway and  
 
also act as a physical barrier to the entry of noxious agents. Recent  
 
studies have shown that nasal epithelial cells play a pivotal role in the  
 
initiation and control of the inflammatory process. They are able to  
 
release biologically active mediators which modulate the function of  
 
other inflammatory cells implicated in the pathogenesis of rhinitis  
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(Cromwell, Hamid et al. 1992; Devalia, Campbell et al. 1993). These  
 
mediators include pro-inflammatory cytokines and cell adhesion molecules,  
 
nitric oxide and arachidonic acid metabolites. Many studies have identified  
 
structurally and functionally related inflammatory cytokines (Miller and Krangel  
 
1992) 
 
7.2.11 Pro-inflammatory cytokines 
 
These mediators are of particular interest in allergic rhinitis as they  
 
influence the activity of immunocytes such as eosinophils, neutrolphils,  
 
T- lymphocytes and mast cells.  Their presence is a key feature of  
 
rhinitis. Studies in vivo and in vitro have shown that HNECs generate a  
 
wide variety of cytokines including IL1β, TNFα, IL-6, IL-5., IL-8, GM- 
 
CSF, RANTES AND MCP-1 (Devalia, Campbell et al. 1993; Kenney, Baker et al.  
 
1994; Davies, Wang et al. 1995; Mullol, Xaubet et al. 1995)  
 
Mullol et al, 1995). However there is no conclusive evidence to date that HNECs  
 
release appreciable amounts of IL-3, IL-4 or IL-13. 
 
The airway epithelial cell-derived cytokines can be divided into 4 groups  
 
according to their main functions: 
 
1) Colony- stimulating factors, which promote the differentiation and  
 
survival of the recruited inflammatory cells 
 
2) Growth factors, which regulate the growth and differentiation of  
 
 airway epithelial cells themselves 
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3) Chemotactic factors which can influence the chemotaxis of the  
 
other inflammatory cells 
 
4) Pro- inflammatory multifunctional cytokines, which can initiate  
 
and amplify events 
 
7.2.12 Colony stimulating factors 
 
Granulocyte-macrophage colony stimulating factor (GM-CSF) 
 
 remains the main cytokine in this group. It serves with two important 
 
 functions in the pathway. Firstly it has chemo-attractant properties as  
 
well as potentiating the differentiation and survival of eosinophils and  
 
neutrophils (Resnick and Weller 1993; Trigg, Manolitsas et al. 1994; Borish and  
 
Rosenwasser 1996; Humbert 1996) demonstrated a significant  
 
correlation between epitheial cell expression of GM-CSF and the number of  
 
activated eosinophils in atopic respiratory mucosa (Trigg, Manolitsas et al. 1994). 
 
 
7.2.13 Growth factors 
 
TGF-β is the most studied transforming growth factor. It is produced  
 
by airway epithelial cells and mediates cell growth and  
 
differentiation (Levine 1995; Borish and Rosenwasser 1996). 
 
It also possesses anti- inflammatory activity in that it inhibits T helper  
 
lymphocytes and cytotoxic (CD-8) lymphocytes and lessens allergic  
 
inflammation by suppressing IL-4 induced IgE production by B  
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lymphocytes (Levine 1995). 
 
7.2.14 Chemotactic factors 
 
Chemotactic factors generated by HNECs include GM-CSF (discussed  
 
earlier), “ released on activation, normal T cell expressed and  
 
secreted” (RANTES), monocytes chemotactic protein-1 ( MCP-1) 
 
 and IL-8, RANTES and MCP-1 both belong to the same chemokine  
 
subfamily. RANTES is a potent eosinophil chemotaxin, MCP-1  
 
induces monocyte and basophil activation and chemotaxis (Schall 1991; Miller and  
 
Krangel 1992; Alam, Stafford et al. 1993). 
 
IL-8 is a potent chemo-attractant for neutrophils and eosinophils (Baggiolini and  
 
Clark-Lewis 1992; Baggiolini, Boulay et al. 1993; Baggiolini and Dahinden 1994). 
 
7.2.15  Multifunctional cytokines 
 
IL-1β, TNF-α, IL-5 and IL-6 are multifunctional cytokines  
 
synthesized and released by airway epithelial cells. They all have pro- 
 
inflammatory effects on a variety of target cells (Devalia, Campbell et al. 1993;  
 
Levine 1995). 
 
IL-1β and TNF-α are potent inducers of cell adhesion α molecules such as  
 
ICAM-1,V-CAM-1 and E-selectin, which facilitate the adhesion and  
 
migration of immunocytes (Montefort, Holgate et al. 1993; Howarth 1995;  
 
Howarth 1995; Howarth, Bradding et al. 1995; Howarth and Holmberg 1995).  
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Other studies indicate that TNFα activates T-lymphocytes, mast cells and  
 
eosinophils and is chemo-attractant for neutrophils and monocytes  (Bradding,  
 
Feather et al. 1993; Bradding, Okayama et al. 1995; Bradding and Holgate 1999).  
 
Several studies have shown the release of inflammatory cytokines and adhesion  
 
molecules by human bronchial epithelial cells is influenced by bacterial induction. 
 
In their hypothesis ,  Khair et al, 1996, described the infiltration and activation of  
 
neutrophils as a result of increased release of pro-inflammatory mediators from  
 
respiratory epithelium. Bacterial products such as endotoxins are known to  
 
influence this activity. 
 
IL6, IL8, TNF-alpha and ICAM-1 have been shown to develop enhanced  
 
expression as a result of bacterial endotoxins. Khair et al in 1995 studied the  
 
effects of erythromycin on the release of IL6, IL8 and sICAM-1 following  
 
haemophilus influenza endotoxin stimulation. Their results showed an increase in   
 
neutrophil chemotaxis within cultured human endothelial cells.  
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Fig.5                            Molecular Structure 
 
 
                   IL-6                          IL-8 
 
 
 
 
 
Courtesy of www.upload.wikimedia.org, Jan 2008 
 
 
  
 
 
IL-5 plays an important role in the proliferation, activation and chemo-attraction of  
 
eosinophils as well as enhancing histamine and leukotriene  release from basophils  
 
(Salvi, Semper et al. 1999).  IL-6 has a role in the cell proliferation and IgE  
 
synthesis.  
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7.2.16  Cell adhesion molecules 
 
Cell adhesion molecules are (CAMs) are specific cell surface receptors  
 
which mediate adhesion of cells to one another and to the extra- cellular  
 
matrix,  (Albelda and Buck 1990; Mackay and Imhof 1993). As a group they  
 
are of importance in the maintenance if tissue  architecture, the inflammatory  
 
response, tumour metastasis and wound healing.  
 
 
7.2.17  Protease- activated receptors 
Protease-activated receptors (PAR) are involved in the contribution of airway 
epithelial cells to the development of inflammation by release of pro- and anti-
inflammatory mediators. Ostrowska et al evaluated the influence of LPS and 
continuous PAR activation on PAR expression level and the release of pro-
inflammatory chemokine IL-8. The study was carried out on primary human small 
airway epithelial cells and two airway epithelial cell lines. LPS specifically up-
regulated expression of PAR-2 agonists but not PAR-1. The authors also found 
PAR-2 but not PAR-1 caused production of IL-8 from epithelial cells. There was a 
potentiation of the stimulation of the IL-8 synthesis and release by PAR-2 in 
human lung epithelial cells. The study has confirmed an interaction between LPS 
and PAR agonists in affecting PAR regulation and IL-8 production. 
The airway epithelium acts as a barrier between the environment and sub-epithelial 
tissues. Winter et al discussed the elements that impose restrictions within the 
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epithelium. The protease-activated receptor-2 (PAR2) receptor is expresses in 
airway epithelium and its activation initiates multiple effects including enhanced 
airway inflammation and reactivity. The study hypothesized that activation of 
PAR2 would interrupt E-caderhin adhesion and compromise the airway epithelial 
barrier. An immediate 50% decrease in trans-epithelial resistance of primary 
human airway epithelium persisted for 6-10minutes. PAR-2 may therefore be 
involved in the pathophysiology of CRS at different sites of activation however 
the effects of protease-activated receptor-2 (PAR-2) stimulation on inflammation 
mechanisms of chronic rhinosinusitis (CRS) are still unknown.  
7.2.18 Nasal Hyper-reactivity 
 
Re-challenge with the allergen following an initial provocation results in  
 
an increase in inflammatory mediator release. It is suggestive of  
 
both mast cell and basophil activation. Most importantly, the dose of  
 
allergen necessary to induce a clinical reaction is significantly reduced  
 
and this phenomenon is thought to be related to the influx of immunocytes  
 
in the late phase response. Oral corticosteroids inhibit this increased  
 
reactivity as well as the late phase response and the cellular influx.  
 
Repeated exposure to antigen maintains a constant inflammatory process  
 
in the nasal mucosa, as seen in perennial rhinitis. 
 
 
7.2.19 Signal transduction in allergic rhinitis 
 
The precise mechanisms underlying allergen-induced release of  
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inflammatory mediators in the nasal mucosa are unclear, although a  
 
number of triggering mechanisms have been postulated. 
 
The first (Classical) mechanism involves allergen-induced activation of  
 
specific epithelial cell surface receptors (probably IgE), which trigger  
 
intracellular signal transduction cascades, leading to alterations in  
 
cytokine gene transcription.  
 
A second mechanism effects by direct allergen induced irritation of mucosal nerve  
 
endings, resulting in neurogenic inflammation. Inflammatory airway disease  
 
appears to have a common initiating pathway with recruitment of adhesion  
 
molecules to sites of inflammation (Montefort, Holgate et al. 1993).  
 
A third mechanism involves allergens with enzymatic properties (e.g  
 
house dust mite allergen), producing direct damage to the epithelial cell  
 
membrane, thus stimulating the synthesis and release of inflammatory  
 
cytokines ( Robinson et al, 1997). A similar mechanism has also been  
 
proposed for non-allergenic pollutant induced cytokine release, in which  
 
aero-pollutants produce epithelial cell damage, leading to free radical and  
 
oxidant formation.  
 
 
7.2.20 Irritative rhinitis 
 
An important and often neglected area of nasal pathology is irritative rhinitis.   
 
Irritative rhinitis is the development of typical rhinitis symptoms  
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in response to a variety of non-allergic stimuli or irritants. These include  
 
cigarette smoke, traffic fumes, perfumes, cold dry air, domestic cleaning agents  
 
and other aero-pollutants. Irritants in high concentration may provoke the acute  
 
nasal symptoms in normal subjects ,however,  in those with existing nasal  
 
symptoms, lower levels of exposure may provoke symptoms. This  
 
is referred to as non-specific nasal hyper-reactivity, and is correlated with an  
 
increase in the number of eosinophils and an increase in vascular permeability in  
 
the nasal mucosa of  allergic rhinitics (Terr, 1991). 
 
 
 
Fig.6       Role of IL-6 in general acute phase response 
 
 
 
 
Courtesy of www.nature.com, Jan 2008 
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Fig.7     World Allergy Organisation- prevalence of rhinitis 
 
                                               
 
Courtesy of www.worldallergy.org, Jan 2008 
 
 
Fig.8                          Role of cytokines in rhinitis 
 
 
Courtesy of www.nature.com, Jan 2008 
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Fig.9                Cytokine reactivity and mast cells 
 
 
 
 
 
 
Courtesy of www.nature.com, Jan 2008 
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Fig.10 
 
 
 
   Mechanism of Immediate Hypersensitivity Response 
 
 
 
 
 
 
Courtesy of www.nature.com, Jan 2008 
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7.3 Allergic rhinitis 
 
7.3.1 Allergic rhinitis- Clinical features 
 
Rhinitis is an inflammatory disease of the nasal mucous membrane.  
 
Although virtually unrecognized 200 years ago, rhinitis has become a  
 
common disease since the industrial revolution and particularly the 20th 
 
century (Vining, 1998). The reason for this dramatic increase is not clear  
 
however rhinitis is frequently mis-diagnosed and under-diagnosed. Increased  
 
awareness of Hay fever may well account for the sharp rise in consultations  
 
regarding this (Sibbald and Rink 1991).  Epidemiological data indicates, however,  
 
environmental pollution may play a role. 
 
7.3.2 Classification 
 
Allergy is the most commonly identified cause of rhinitis. The nasal inflammatory  
 
process may arise from a number of systemic diseases and anatomical  
 
abnormalities as well as non-allergic stimuli. 
  
A clinical classification of rhinitis has been updated by the ARIA Guidelines in  
 
2008 as follows: 
 
1. ‘Intermittent’- symptoms present for 
 
• <4 days a week 
 
• Or for <4 consecutive weeks 
 
 
2. ‘Persistent’ means that the symptoms are present 
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• More than 4 days a week 
 
• And for more than 4 consecutive weeks 
 
 
3. ‘Mild’ that symptoms are present but not troublesome and that none of the  
 
following items are present: 
 
• Sleep disturbance 
 
• Impairment of daily activities, leisure and/or sport 
 
• Impairment of school or work 
 
4. ‘Moderate/severe’ means that one or more of the following items are 
present: 
 
• Sleep disturbance 
 
• Impairment of daily activities, leisure and/or sport 
 
• Troublesome symptoms 
 
 
 
7.3.3 Characteristics of seasonal allergic rhinitis 
 
Seasonal allergic rhinitis (SAR), also known as Hay Fever, is defined as  
 
nasal inflammation characterised by itching of the respiratory tract  
 
mucous membrane, sneezing rhinorrhoea, post-nasal drip and nasal  
 
blockage with an identified seasonal trigger such as tree pollen, grass  
 
pollen or mould. 
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7.3.4 Characteristics of perennial allergic rhinitis 
 
Perennial allergic rhinitis ( PAR) is characterized by year-round nasal  
 
inflammation with a defined perennial trigger, commonly dust, feathers  
 
or animal dander. The symptoms are similar to SAR although there is a  
 
tendency towards increased nasal blockage and fewer symptoms of  
 
itching, as the nasal mucosa becomes increasingly thickened by chronic 
 
cellular influx oedema. 
 
Other symptoms include anosmia, conjunctivitis and facial pain. 
 
It is important to note that in the majority of case, aetiology is often not  
 
clear-cut and overlap may exist between precipitating factors. An  
 
example of this is a patient with PAR may suffer seasonal exacerbations  
 
during the grass pollen season ( typically June to July) together with  
 
flare-ups attributable to smoke, perfume or traffic fumes (Djukanovic, Feather et  
 
al. 1996). Risk factors such as current urban residence or birthplace,  
 
over-crowding, nasal septal deviation, chronic rhinosinusitis and polyposis appear  
 
to result in an increased risk of PAR (Min, Jung et al. 1997). 
 
7.3.5           Physical findings in allergic rhinitis 
 
Physical abnormalities are not a major feature of the disease. Classically  
 
there is a pale, boggy and bluish nasal membrane. 
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7.3.6  Investigations 
 
7.3.6.1         Skin prick testing  
 
Proof that nasal allergy is present requires the demonstration of allergen-  
 
specific IgE in the patient. The most widely used technique is the skin  
 
prick test in which the skin is pricked through a drop of antigenic extract  
 
using a specifically designed needle, introducing approximately 5ηl of  
 
extract into the skin. The Type I hypersensitivity wheal and flare reaction  
 
is compared with the results of negative (diluent) and positive (histamine)  
 
controls. 
 
7.3.6.2       Scratch Testing  
 
The test antigen is placed on the area of skin scratched to remove keratinized  
 
layers. This test lacks specificity and sensitivity and is now no longer 
 
recommended. 
 
7.3.6.3       Intra-dermal Dilution Testing 
 
Standard quantities of a variety of antigen dilutions are placed intra-dermally  
 
by injection. This enables identification of the exact starting dose but cannot  
 
predict the final optimum therapeutic dose. It is considered as good as, if not  
 
better than, skin-prick testing. It does entail increased time and personnel costs  
 
and thereby is not commonly available. 
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7.3.6.4         Blood tests 
 
1) RAST  
The discovery of  IgE as the antibody for the classical immediate 
allergic reaction((Ishizaka, Ishizaka et al. 1966) lead to the development  
of the in vitro Radioallergoabsorbent test(RAST) for its detection in  
serum (Wide, Bennich et al. 1967).  In vitro tests are considered more  
specific but less sensitive than skin testing and in the UK are generally  
used only if there is a contradiction to skin prick testing e.g    
dermatographia or inability to stop antihistamines. 
2) Blood eosinophil count 
This test has been related to history since eosinophilia is often found   
in rhinitis but  is not as striking  as asthma, and a normal eosinophil  
count does not rule out a diagnosis of allergic rhinitis. 
 
7.3.6.5 Dust and perennial allergic rhinitis 
Dust is the major cause of perennial allergic rhinitis(PAR) in sensitive  
individuals. “House dust” as a unique antigen does not exist but rather  
contains antigens such as dust mite products, animal dander, mould and  
cockroach. 
 
 House dust mite 
 
The most important allergens in UK “house dust” are the products of dust  
 
mites Dermatophagoides pteronyssinus and Dermatophagoides farinae. 
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The dust mite thrives in the modern household, since optimum  
 
environmental conditions for mite growth include temperature 17-25°C  
 
and relative humidity >50%. Food sources for mites includes scales from  
 
human skin or the fungi that grow on them, and mites are found  
 
predominantly in bedding, upholstery, furniture and carpets (Tovey, Chapman et  
 
al. 1981). Two major allergen groups (1 and 2) have been  
 
identified as most important, because the majority of mite-sensitive patients  
 
demonstrate immediate hypersensitivity to them. These major allergens  
 
appear to be digestive enzymes secreted in the dust mite faeces (Tovey, Chapman  
 
et al. 1981; Chua, Stewart et al. 1988; Thomas, Heap et al. 1991; Yasueda, Mita et  
 
al. 1993). 
 
The allergens are soluble proteins with a molecular weight of 14-25kDA,  
 
which easily penetrate the nasal mucosa to react with specific IgE (Roche, Chinet  
 
et al. 1997). 
 
The majority of patients with dust allergy experience symptoms once the 
 
number of dust particles in the air reaches 50/m3. 
 
 
7.3.6.6 Epidemiology of allergic rhinitis 
 
Burden & prevalence of disease 
 
Although the effects of PAR and SAR are unlikely to be life threatening,  
 
one must bear in mind the great burden of disease and loss of quality of  
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life for the estimated 6 million UK sufferers (Frank and Rabin 1989). 
 
In the USA direct and indirect costs of allergic rhinitis total well above $500  
 
million per annum, with the disease estimated to be responsible for 10  
 
million days lost from work and 8 million visits to the physician ( NSAID  
 
Task  Force  Report, 1979). 
 
The prevalence of diagnosed SAR amongst patients consulting general  
 
practitioners is reported to be 19.7 per 1000 in England and Wales (Ross and  
 
Fleming 1994) 
 
Estimates of the prevalence of allergic rhinitis in different countries vary 
 
between 0.5-28% in children and 0.5-15% in adults (Aberg, Hesselmar et al. 1995;  
 
Strachan, Butland et al. 1996). 
 
Within the UK a study of 17,414 children followed to age 23 years  
 
showed that the prevalence of self reported allergic rhinitis was 14.1% in  
 
Scotland rising to 20% in south-east England (Strachan 1989). 
 
This north/south gradient was similarly demonstrated by Fleming &  
 
Crombie who showed that the proportion of the population consulting their   
 
General Practitioner for SAR was higher in the south than in the north of  
 
Britain (Fleming 1989). 
 
There is little doubt that the prevalence of allergic rhinitis has increased  
 
dramatically over the last 30 years, as illustrated by the epidemiological  
 
studies of school children in Aberdeen,  (Ninan and Russell 1992) and in  
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eastern Switzerland (Burkholter & Schiffer, 1995). 
 
 
7.3.6.7 Associated conditions and complications 
 
There is a well known association between allergic rhinitis, asthma and  
 
eczema (Sibbald and Rink 1991). The prevalence of asthma amongst  
 
persons with SAR are four to six fold higher than the general population  
 
(Broder, Higgins et al. 1974). The prevalence of allergic rhinitis amongst  
 
asthmatics is 28-50% as compared with its estimated population  
 
prevalence of 10-20%  (Weeke 1987; Spector 1997). 
 
Allergic rhinitis may be complicated by a number of conditions including  
 
nasal polyposis, infectious rhinosinusitis and otitis media. 
 
 
7.3.6.8 Treatment 
Management of allergic rhinitis may appear complex. The importance of early 
treatment has been discussed by Rudack et al in 2007 (Rudack, 2007). Allergic 
Rhinitis is associated with other co-morbidities and early appropriate treatment is 
imperative. Anti-histamines and glucocorticoids remain a keystone in the medical 
management however more recently immunotherapy has been the sole treatment. 
There is a broad spectrum of pharmacotherapeutic groups that are currently 
available which will be discussed further now alongside non- pharmacotherapeutic 
treatment. 
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Environment changes 
 
Environmental control is considered the first line in the management of allergic 
rhinitis. Reducing exposure to high dose pollen counts and minimising household 
pollen by closing windows and using air conditioning. Furnishing living areas 
without carpets or plants with a minimum of upholstery is advisable.  
Pharmacological therapy 
Antihistamines provide H1- receptor blockage. First- generation antihistamines 
have significant sedating effects and can produce tachyphylaxis. Second generation 
antihistamines do not produce this problem. Pseudo-ephedrine is effective for nasal 
obstruction. It can be used alone or in combination with anti-histamines. Topical 
steroid sprays are very effective for nasal allergy symptoms. Several new anti-
histamine and mast cell stabilizers are also available. Anticholinergics are also 
used for chronic rhinorrhoea. Oral antileukotrienes agents such as montelukast 
have also proved very helpful.  
Allergy immunotherapy (desensitization) is indicated for individuals who fail 
environmental control and pharmacotherapy. Therapy is based upon antigen 
sensitivity delineated by allergy testing, either in-vitro or skin (Bradding et al, 
1999). It is however a costly and inconvenient treatment requiring weekly 
injections for up to two to five years with a potential risk of anaphylaxis. 
Contraindications include poorly controlled asthma and induction during 
pregnancy. There is a 60% long-term control of symptoms.  
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The ARIA guidelines (Allergic Rhinitis and its Impact on Asthma) have provided a 
practical and staged approach to treatment.  Intranasal steroids remain the single 
most effective therapeutic agent in the treatment of allergic rhinitis. 
 
7.4  CHRONIC RHINOSINUSITIS 
 
Chronic rhinosinusitis is one of the most prevalent chronic illnesses  
 
affecting the western world.  These infections are the leading cause of  
 
acute morbidity and of school and work absenteeism.  
 
It accounts for 20% of adult antibiotic prescriptions were written for a  
 
diagnosis of acute sinusitis.  For the purposes of this thesis we focus on skin  
 
prick test positive allergic rhinitis and chronic rhinosinusitis confirmed by a  
 
pre- operative CT-scan,  (Hadley 2001). 
 
Classification of rhinosinusitis has been clarified by EPOS ( European Paper on  
 
Rhinosinusitis and Nasal Polyps). 
 
Rhinosinusitis is defined as inflammation of the nose and paranasal sinuses 
characterized by two or more symptoms, one of which should be either nasal 
blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip): 
+/- facial pain/pressure 
+/- reduction or loss of smell 
And either  
• Endoscopic signs of  
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-polyps and/or 
-mucopurulent discharge primarily from middle meatus and or 
-oedema/mucosal obstruction primarily in middle meatus 
And/or 
• CT changes: 
- Mucosal changes within the ostiomeatal complex and/or sinuses 
Severity of the disease can be divided into mild, moderate and severe based on 
total severity visual analogue scale 
(VAS) score (0-10cm): 
Duration of disease : 
Acute: <12 weeks with complete resolution of symptoms 
Chronic:>12 weeks symptom without complete resolution of symptoms  
The management costs involved in chronic rhinosinusitis are significant in terms of  
 
both medications and work time lost, and thereby research  is needed to  
 
identify the patients for potential complications. Injudicious usage and  
 
indiscriminate over-prescriptions of antibiotics have fostered the rapid  
 
development of penicillin-resistant organisms over the past two decades. Drug  
 
resistant Streptococcus pneumoniae and beta-lactamase-producing Haemophilus  
 
influenza and Moraxella catarrhalis are perceived to be the main focus of attention,  
 
forcing the need to consider alternatives in antibacterial management. Appropriate  
 
medical management of this common problem requires a systematic approach with  
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consideration of adjunctive therapy. 
 
Chronic rhinisosinusitis is usually defined as sinus infection persisting for  
 
more than 3 months. Symptoms are perhaps more clearly defined than in allergic  
 
rhinitis.  These include nasal stuffiness, postnasal drip, anosmia, facial fullness and  
 
malaise (Bajracharya et al, emed- Jan 2003). Allergic and non-allergic  
 
rhinitis, anatomic obstruction of the ostiomeatal complex are known risk  
 
factors (Steinke and Borish 2004).  
 
Knowledge of the anatomy of paranasal sinuses is an essential tool in  
 
understanding the pathophysiology and management. Four pairs of  
 
sinuses are lined with ciliated pseudo-stratified columnar epithelium.  
 
Goblet cells are columnar cells. The mucous is attached directly to the  
 
bone thereby involvement of bone, orbital and intracranial compartments  
 
occur in inadequately treated cases. The maxillary, frontal and anterior  
 
ethmoid sinuses drain through their ostia located at the ostiomeatal 
 
complex within the middle meatus. 
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Fig.11                  Anatomy of the paranasal sinuses 
 
          
 
 
 
Courtesy of www.merck.com, Jan 2008 
 
 
Fig.12          Nasal and paranasal sinuses 
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Courtesy of www.pubmedcentre.nih.gov, Jan 2008 
 
The posterior ethmoid and sphenoid sinuses open into the superior meatus 
 
respectively. The maxillary ostium connects to the nasal cavity by  
 
mucociliary clearance. The inferior floor of the maxillary sinus is the  
 
tooth-bearing part of the maxilla  and dental infections can easily extend  
 
to the maxillary sinus. Even though usually colonized by bacteria the  
 
sinuses are typically sterile. Mechanical obstruction at the ostiomeatal  
 
complex secondary to anatomic factors or mucosal oedema arising 
 
secondarily to a acute viral or allergic rhinitis often triggers the stasis of  
 
secretions within the sinuses. This mucous stagnation effects the growth  
 
of various pathogens. Initially, resulting acute sinusitis involves only one  
 
type of aerobic bacteria however a mixed flora and anaerobic organisms   
 
and occasionally fungus contribute to the pathogenesis. Chronic sinusitis  
 
ensues in those where acute sinusitis has not responded to treatment or those who  
 
have not received treatment.  
 
The role of bacteria in the pathogenesis of chronic rhinosinusitis is  
 
currently in question. In the United States chronic rhinosinusitis affects  
 
approximately 32 million persons each year and accounts for 11.6%  
 
sickness in offices. It ranks fifth compared to all diseases in frequency of  
 
antibiotic use. Internationally, chronic rhinosinusitis is a common disease  
 
worldwide, particularly in places where the atmosphere is damp.  
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Temperate climates along with higher concentrations of pollens are  
 
associated with a higher prevalence as in the northern hemisphere. 
 
Because of its persistent nature, chronic sinusitis can become a significant  
 
cause of malaise and reduced quality of life and productivity of the  
 
affected person. Chronic sinusitis is associated with complications such  
 
as brain abscess and meningitis which can produce significant morbidity  
 
and mortality.  
 
 
7.4.1  Aetiology of chronic rhinosinusitis 
 
Chronic rhinosinusitis is observed in all races and both sexes are affected 
 
equally. All age groups are affected. 
 
 
7.4.2  Clinical history of chronic rhinosinusitis 
 
Chronic rhinosinusitis manifests more subtly than acute sinusitis. The  
 
typical symptoms of acute sinusitis, namely fever and facial pain, are absent. 
 
Patients usually present with the following symptoms: 
 
- Nasal stuffiness 
- Nasal discharge 
- Postnasal drip 
- Facial pain 
- Facial fullness, discomfort and headache 
- Chronic unproductive cough 
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- Hyposmia 
- Sore throat 
- Fetis breath 
- Malaise 
- Exacerbation of asthma 
- Dental pain 
- Visual disturbances 
- Sneezing 
- Stuffy ears 
- Unpleasant taste 
- Fever of unknown origin 
 
7.4.3  Classification and Diagnosis of chronic rhinosinusitis 
 
The European Position on Rhinosinusitis and Nasal Polyps in 2007 is discussed 
above. Severity of the disease can be divided into mild, moderate and severe based 
on visual analogue score (VAS) (0-10cm) 
Mild= VAS 0-3 
Moderate=VAS>3-7 
Severe= VAS>7-10 
To evaluate the total severity the patient is asked to indicate on VAS the answer to 
the question: 
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HOW TROUBLESOME ARE YOUR SYMTOMS OF RHINOSINUSITIS? 
          
     10cm 
Not troublesome      Worst thinkable troublesome 
AVAS>5 is considered to affect to affect quality of life 
Duration of the disease  
Acute: <12 weeks with complete resolution of symptoms 
Chronic>12 weeks symptoms without complete resolution of symptoms- may also 
be subject to exacerbations 
Diagnosis  
Symptoms for less than 12 weeks. 
Sudden onset of two or more symptoms, one of which should be either nasal 
blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip): 
+/- facial pain/pressure 
+/-reduction /loss of sense of smell 
With free intervals if problem is recurrent; validation by telephone or interview 
asking questions on allergic symptoms, i.e, sneezing, watery rhinorrhoea, nasal 
itching and itchy watery eyes 
Chronic rhinosinusitis has also recently been classified into four types based  
on its pathophysiologic process, (Steinke and Borish 2004).  
 
A minority of patients have chronic infectious sinusitis. A second form  
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chronic inflammatory sinusitis is believed to arise from chronic sinus ostia  
 
occlusion with resulting recurrent infections and damage to the sinus  
 
epithelium. Chronic inflammatory infiltration ensues with mononuclear cell  
 
proliferation.  
 
Allergic fungal sinusitis is epithelium a severe T- helper 2 (Th2)  
 
inflammatory process in response to usually benign fungal colonisation and  
 
provides a third category. Chronic hyperplastic eosinophilic sinusitis(CHES), is an  
 
inflammatory disease hallmarked by a prominent accumulation of eosinophils, is  
 
considered a fourth subtype. CHES is frequently associated with nasal polyposis,  
 
allergic sensitization, asthma, and aspirin sensitivity. Cysteinyl leukotienes are able  
 
to induce vascular leakage, mucous secretions, myofibroblast proliferation, and  
 
eosinphil recruitment, adhesion and survival, (Steinke and Borish 2004).  
 
These are all important in the pathophysiology of  CHES. 
 
An open-labelled study has shown improvement in nasal symptom scores  
 
but not in objective parameters in 32 patients with CRS treated with  
 
montekulast, a leukotriene-modifying drug. This drug type appears to be  
 
safe and attractive option for the treatment of CHES. Leukotriene  
 
treatment of this last category, CHES, is the focus of many reviews. 
 
Surgery is often beneficial for anatomic defects or chronic inflammatory  
 
sinusitis, however have been disappointing for CHES, (Kennedy 1992; Lavigne,  
 
Nguyen et al. 2000). Important advancements include the anti-inflammatory  
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properties of macrolide in CHES. a review article has been published by (Scadding  
 
2004). 
 
The underlying cause of CHES is unknown and its chronic inflammatory 
 
disease characteristic by not only eosinophils but also fibroblasts, mast  
 
cells, goblet cells, and Th2 lymphocytes. It does not appear to be an  
 
infectious process, but bacteria and fungi may act as immune stimulators or  
 
super-antigens.  
 
There does appear to be a relation between CHES and allergic disease.  
 
Steinke and Borish outlined their work on the systemic inflammation of  
 
allergic disease and how it interacts with sinusitis in a recent review.  
 
Twenty-five to 58% of individuals with sinusitis have allergic rhinitis  
 
and allergic sensitivity, especially to perennial allergens, which increase  
 
the risk for CHES (Savolainen 1989; Emanuel and Shah 2000; Gutman, Torres et  
 
al. 2004). Half of CHES patients also have clinically evident asthma. It has been  
 
argued that CHES and asthma share similar histopathological features and are the  
 
same inflammatory process manifested in different sites, (Ponikau, Sherris et al.  
 
2003). In recent years the focus has been on the association between  
 
gastrointestinal reflux disease (GERD) and its role in upper and lower airway  
 
disease. There are several studies supporting a worsening role for GERD in asthma  
 
but there is fewer data on sinusitis. A review of the literature performed by  
 
(Weaver 2003) found a modest evidence for a positive association between GERD  
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and sinusitis. A small open-label pilot study was performed to examine the  
 
effects of omeprazole in CRS patients, using GERD patients as controls.  
 
There was a high prevalence of GERD in CRS patients and treatment with  
 
proton pump inhibitor had an improvement in sinus symptoms, (DiBaise, Olusola  
 
et al. 2002).This area requires further investigation.  
 
Clarithromycin has been shown to inhibit transforming growth factor and  
 
nuclear factor from nasal biopsy samples as well as the effects on suppressing  
 
interleukin-5, interleukin-8, and granulocyte-macrophage colony-stimulating factor  
 
was equal to prednisolone in nasal biopsy samples of patients with CRS(Wallwork,  
 
Coman et al. 2004). There has been limited in vivo work in the United States  
 
however a good deal of data is being produced in Japan. Fifty-six patients had an  
 
overall improvement based on subjective and objective criteria, (Katsuta, Osafune  
 
et al. 2002). Tamaoki (Tamaoki 2004) have shown that LPS up-regulates the  
 
expression of ICAM-1 when added to cultured rat tracheal epithelial cells. LPS 
endotoxin comprises a major portion of cell walls of gram-negative bacteria and 
interacts with a variety of cell types, including neutrophils, basophils and 
monocytes. Studies have demonstrated that LPS increases microvascular 
permeability, neutrophil chemotaxis, accumulation into airway wall and, hence 
neutrophil airway inflammation. 
 
7.4.4  Physical signs of chronic rhinosinusitis 
 
A diagnosis chronic rhinosinusitis is made if symptoms last longer than 12 weeks 
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Two or more symptoms, as described above, are essential.one of which should be 
either nasal blockage/ obstruction/congestion or nasal discharge (anterior/posterior 
nasal drip):  
+/- facial pain/pressure 
+/-reduction or loss of smell 
With validation by telephone or interviews asking questions on allergic symptoms; 
i.e sneezing, watery rhinorrhoea, nasal itching and itchy watery eyes. If positive, 
allergy testing should be performed. 
Physical examination may reveal a variety of findings. 
-Pain or tenderness on palpation over frontal or maxillary sinuses. 
 
-Oropharyngeal erythema, purulent secretions 
 
-Dental caries 
 
Endoscopic examination findings: 
  
-Nasal mucosal erythema, oedema 
 
-Purulent secretions 
 
-Nasal obstruction due to deviated nasal septum or hypertrophied  
 
 turbinates  
 
-Nasal polyps 
 
Ophthalmic manifestations include: 
 
-Conjuntival congestion 
  
-Lacrimation 
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-Proptosis, extraocular muscle palsies and visual disturbances (when  
 
 orbital extension). 
 
 
7.4.5  Causes of chronic rhinosinusitis 
 
The bacterial pathogens and their roles are well defined in the aetiology  
 
of acute sinusitis. Streptococcus influenzae and Mozarella catarrhalis  
 
account for more than 70% of cases of acute sinusitis. 
 
The role of viruses in the aetiology of acute sinusitis has been documented.  
 
Bacterial sinusitis complicated up to 20% of viral rhinitis cases. While the  
 
microbiology of acute sinusitis has also been established, researchers disagree on  
 
the microbiology of chronic rhinosinusitis. Some studies have documented  
 
anaerobes as the prominent pathogens in chronic rhinosinusitis, while others  
 
contradict this. 
 
The reasons for the variable growth of microbes in the samples obtained  
 
from chronic sinusitis reflect exposure of patients to various broad-spectrum  
 
antibiotics as well as to the difference in the exact role of these microbes in the  
 
pathogenesis of chronic sinusitis. 
 
Increasing attention is being focused on the ostio-meatal obstruction,  
 
allergic, polyps, occult and dental diseases, while the role of bacteria is  
 
being reduced to that of opportunistic colonizer.  
 
The following bacteria have been reported in samples obtained through  
 
endoscopy or sinus puncture sinusitis: 
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1 Staphylococcus aureus 
2 Coagulase-negative staphylococci 
3 H influenzae 
4 M catarrhalis 
5 S pneumoniae 
6 Streptococcus viridans 
7 Streptococcus intermedius 
8 Pseudomonas aeruginosa 
9 Nocardia species 
10 Anaerobic bacteria 
The following fungi have been reported in samples obtained through endoscopy or  
 
sinus puncture 
 
1 Aspergillus species 
2 Cryptococcus neoformans 
3 Candida species 
4 Sporothrix schenckii 
5 Alternaria species 
 
The following conditions and risk factors predispose patients to the  
 
development of chronic rhinosinusitis: 
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1 Anatomic abnormalities affecting the ostiomeatal complex (e.g,  
 
septal deviation, paradoxical turbinates, concha bullosa, Haller  
 
cells) 
 
2 Allergic rhinitis 
 
3 Nasal polyps 
 
4 Nonallergic rhinitis (e.g, vasomotor rhinitis, rhinitis  
 
medicamentosa, cocaine abuse) 
 
5 Nasotracheal intubation 
 
6 Nasogastric intubation 
 
7 Hormonal (e.g, puberty, pregnancy, oral contraception) 
 
8 Tumoral obstruction 
 
9 Immunologic disorders (e.g, common variable immunodeficiency,  
 
immunoglobulin A deficiency, AIDS) 
 
1 Cystic fibrosis 
 
2 Primary ciliary dyskinesia, Kartagener syndrome 
 
3 Wegener’s granulomatosis 
 
4 Repeated upper respiratory tract infections 
 
5 Smoking 
 
6 Environmental pollution 
 
7 Gastrooesophageal reflux disease 
 
8 Perichondritis/significant dental disease 
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It is important to consider other co-existing conditions that are  
 
associated with chronic rhinosinusitis. 
 
These include the following: 
 
1 Temporomandibular Joint Syndrome 
 
2 Asthma 
 
3 Other chronic rhinitis 
 
4 Nasal and sinus cavity tumours 
 
5 Facial pain attributable to other causes 
 
6 Nasal polyps 
 
It has been shown by many studies that there is no correlation between  
 
nasal flora and culture from sinuses (Lacroix, Ricchetti et al. 2002). Nasal  
 
swab cultures have no diagnostic value. Occasional, an abundance of  
 
eosinophils in the nasal smear may point to the allergic nature of the  
 
mucosa. Specimens obtained from sinus openings through an endoscope  
 
correlate well with specimens obtained from respiratory brushings. Routine  
 
blood cell counts and sedimentation rates are generally unhelpful. In severe  
 
cases, blood cultures, including fungal blood cultures, may be helpful. 
 
Allergy testing must be carried out if a sensitivity is thought to be the  
 
underlying cause. 
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7.4.6  Investigation of chronic rhinosinusitis 
 
The cornerstone for diagnostic workup of chronic sinusitis is the  
 
radiological examination. 
 
Plain radiograph 
 
The routine radiograph has limited value in the evaluation of sinusitis  
 
however it has been thought that mucosal thickenings or sinus opacities  
 
may be observed. Air fluid levels are not a common feature in chronic  
 
sinusitis and plain films do not show ethmoid sinuses or the ostiomeatal  
 
complex well. 
 
7.4.6.1 CT Scan  
 
Contrast-enhanced CT scan is the current radiologic standard  
 
for the evaluation of sinus to scanning may be prohibitively expensive or  
 
medically unnecessary. CT scans are usually indicated after failure of  
 
maximal medical therapy and before surgical planning and in exclusion  
 
of possible neoplasms. A coronal CT scan of the sinus correlates best  
 
with the surgical approach, permitting visualization of the ostiomeatal  
 
complex, sinus cavities and surrounding structures such as the orbit,  
 
cribriform plate, and dental pathologies are visualized well. Specific  
 
entities in the sinus cavity such as polyps can be identified. 
 
A CT scan combined with endoscopic examination helps the surgeon to  
 
make operative decisions. Most centres now offer limited sinus CT scans  
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consisting of 5-12 coronal cuts.  
 
 
7.4.6.2 MRI 
 
MRI is generally reserved only for complex cases. Soft tissue contrast is  
 
better with MRI. Neoplasms, orbital and intracranial complications as  
 
well fungal sinusitis can be better evaluated. 
 
Procedures 
 
Appropriate cultures of the ostiomeatal complex region should guide  
 
otolaryngologists to a proper choice of an antimicrobial regimen, but  
 
culture of nasal secretions traditionally has not been correlated with the  
 
findings on antral puncture. The gold standard of diagnosis has  
 
traditionally been culture of the maxillary sinus via antral puncture, however, 
 
recent evidence has linked the association of endoscopic-guided  
 
cultures (obtained with fine- wire swabs) to those of antral aspirates.  
 
85.75% of endoscopic-guided cultures corresponded to bacteria present in  
 
the maxillary antrum. More recently Vogen et al noted that endoscopically  
 
guided meatal cultures were accurate and identified the predominant  
 
bacterial pathogen in 90% of cultures. Laboratory evaluation of  
 
rhinosinusitis may include nasal cytology (looking for neutrophils), sweat  
 
chloride tests and mucociliary transport studies, which evaluate the  
 
timing of the passage of saccharin through the nose to the posterior  
 
oropharynx.  
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7.4.7 Management 
 
Treatment should be based on the severity of symptoms 
 
Mild- VAS 0-3  Moderate to Severe-VAS>3-10 
 
Treat with topical steroids, nasal douching/lavage. 
In failure to improve then supplement a three month course of macrolides. If the 
symptoms are refractory to medical treatment, a CT scan is required to identify 
indications for surgery. 
Ragab et al conducted the first prospective randomized trial evaluating and 
comparing surgical and medical management of polypoid and non polypoid 
chronic rhinosinusitis (Ragab, S. M., V. J. Lund, et al. (2004). "Evaluation of the 
medical and surgical treatment of chronic rhinosinusitis: a prospective, 
randomised, controlled trial." Laryngoscope 114(5): 923-30). Their work analysed 
the outcome of ninety patients over a one year period with CRS using visual 
analogue scores(VAS), the Sinonasal Outcome Test-20(SNOT-20) and other 
methods of post treatment assessments. The study concluded that medical 
treatment should be the mainstay of management in the form of topical steroid, 
nasal douche with a three month course of macrolide antibiotic. In refractory cases 
surgical treatment may be applied. Ragab et al also concluded the presence of 
polyps was not in fact a poor prognostic factor in the efficacy of either treatment.  
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7.4.8 Medical Management 
 
Medical therapy is in some cases considered an adjunct to surgical treatment and  
 
is directed toward colonizing infections, reducing oedema of sinus tissues  
 
and facilitating the drainage of sinus secretions. The role of bacteria is  
 
debatable, however, when diagnosed early and intensively treated with  
 
oral antibiotics, topical nasal steroids, a number of patients have relief  
 
from symptoms and many can be cured. It is imperative to assist medical  
 
therapy, in particular if unsuccessful, by evaluating the following: 
 
1 Control of predisposing factors such as risk factors and aetiologies  
 
for the development of chronic sinusitis or modify these factors in  
 
the management of chronic sinusitis. 
 
2 Viral upper respiratory tract infections; Reduce viral exposures by  
 
improved personal hygiene. Respiratory tract infections are  
 
controversial. 
 
3 Environmental factors: Reduce exposure to dust, moulds, cigarette  
 
smoke and other environmental hazards. 
 
4 Allergic rhinitis: Environmental control, anti histamines,  
 
cromolyn, topical steroids, or immunotherapy. 
 
5 Patients with adult chronic sinusitis may benefit from control of  
 
GERD. GERD has increasingly ailments such as asthma and  
 
chronic sinusitis. The exact relationships and mechanisms are currently  
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under evaluation. 
 
6 Immunodeficiency states: Appropriate control of various  
 
congenital and acquired immunodeficiency. 
 
7.4.9 Symptomatic Measures 
 
Symptoms may be relieved with topical decongestants, topical steroid, antibiotics  
 
and nasal saline douches. Steam inhalation and nasal saline irrigation may help by  
 
moistening dry secretions, reducing mucous. 
 
Fungal sinusitis 
 
Fungal sinusitis can manifest in different ways. Acute invasive fungal sinusitis is  
 
observed in patients who are immune-suppressed or diabetic. Aspergillus, Mucor  
 
and  Rhizopus are the main cause. The condition requires urgent work up and  
 
aggressive medical management. Chronic fungal sinusitis is usually observed   
 
in patients who are immune-competent. Surgical drainage may necessitate. 
 
Mycetomas or fungal balls may be asymptomatic or may manifest as chronic  
 
sinusitis. Allergic fungal sinusitis usually manifests as nasal polyps in 
 
allergic sinusitis. Surgical treatment may again be necessary. Persistent or  
 
recurrent episodes of sinusitis despite appropriate medical therapy necessitate  
 
referral to a specialist for endoscopic evaluation and CT scanning, mandatory to  
 
exclude surgically amenable conditions. In the event of orbital involvement,  
 
an opthalmological opinion is necessary. 
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7.4.10     Pharmacotherapy 
 
7.15.1 Topical decongestants 
 
These are alpha- adrenergic agonists that act by constricting dilated  
 
mucosal capillaries. Pseudoephedrine hydrochloride, phenylephrine  
 
hydrochloride, and xylometazoline are available for use in the topical  
 
form. The resulting vasoconstriction of mucosal capillaries promotes  
 
shinkage of the swollen nasal mucosa. All adrenergic topical preparations  
 
should be with caution as topical agents can produce rebound  
 
vasodilatation on discontinuation and rhinitis medicamentosa with  
 
prolonged use. 
 
7.4.10  Topical corticosteroids 
 
These are particularly effective for chronic sinusitis associated with an  
 
infection. Recent studies show that the medical management of bacterial  
 
rhinosinusitis can be enhanced with the addition of intranasal steroids.  
 
Topical intranasal steroids have marked anti-inflammatory actions to  
 
reduce the vascular permeability and to inhibit the release of chemical  
 
mediators, especially histamine, leukotienes and others (Mullol, Lopez et al. 1997).  
 
They reduce cellular influx to the inflammatory site and modify both  
 
the early and late-phase responses in rhinitis. The same principles hold true in  
 
sinusitis; topical intranasal steroids should have marked beneficial effects  
 
due to similarity of respiratory epithelium in the nose and the paranasal  
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sinuses. Topical nasal steroids are advocated in hyperplastic polypoid  
 
rhinosinusitis (Damm, Jungehulsing et al. 1999). Hamilos, Thawley et al.  
 
1999, demonstrated gradual response of the nasal polyps to intranasal steroids and  
 
showed that they also reduced nasal polyp inflammation but not the expression of  
 
pro-inflammatory cytokines.  
 
Damm et al. 1999 combined the use of oral steroids and intranasal steroids and  
 
found markedly reduced polypoid disease, but this medication did not affect the  
 
anterior ethmoid area and did change the need for consideration of surgery. 
 
Topical steroids along with systemic antibiotics are now key 
 
components of the medical armamentarium. Fluticasone proprionate is an  
 
example (Hamilos, Thawley et al. 1999)and is uses in particular with allergic  
 
and vasomotor rhinosinusitis and also rhinosinusitis medicamentosa as well  
 
as in the prophylaxis of nasal polyps. Plasma concentrations remain very  
 
low following long-term application. 
 
 
7.4.12   Antihistamines 
 
Allergic rhinitis is a cause for rhinosinusitis. Antihistamines may  
 
be beneficial in adjunctive therapy for the patient with a history of allergic  
 
rhinitis. The type of antihistamine is controversial. The first generation of  
 
antihistamines may tend to reduce the rhinorrhoea associated with the  
 
inflammation, but drying effects of these products thicken sinus  
 
secretions and possibly slow mucociliary clearance. The newer second- 
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generation antihistamines (acrivistine, cetirizine, fexofenadine, and  
 
loratidine) would be favoured in patients with a history of allergy.  
 
Topical antihistamines currently available (azelastine, levocabastine)  
 
are extremely potent histamine blockers, but no controlled studies of  
 
their utilization in rhinosinusitis are available at this time. 
 
 
 
7.4.13   Topical nasal sprays 
 
Nasal saline spray and steam inhalation help by moistening dry secretions  
 
and their viscosity. Substantial symptomatic relief is gained in some  
 
patients. Saline spray loosens mucous secretions to help extrusion of  
 
mucus from the nose and sinuses. 
 
7.4.14    Mast cell stabilizers 
 
Cromolyn sodium inhibits degranulation of sensitized mast cells  
 
following their exposure to specific antigens. 
 
 
7.4.15   Expectorants 
 
Although there are no controlled studies on the efficacy of mucolytics in   
 
chronic sinusitics, they have been helpful in ameliorating some  
 
symptoms. 
 
Inpatient care is indicated if orbital or intracranial complications ensue.  
 
Patients who are immunosuppressed and paediatric patients may need  
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in-patient care depending on the progression of infections. 
 
Continued outpatient medical treatment with nasal decongestants and  
 
topical steroids is important in monitoring the progress of cases. 
 
Certain conditions cause a predisposition to chronic sinusitis.  
 
 
7.4.16    Antibiotics 
 
The goals of pharmacotherapy are to eradicate the infection, reduce  
 
morbidity and prevent complications. Antibiotics have traditionally been used as  
 
effective eradicators of  bacterial sinus infections. It has been shown that  
 
antibiotics improved symptoms and decreased or eradicated bacteria from  
 
the maxillary sinus (Gwaltney, Wiesinger et al. 2004). When used  
 
appropriately, antibiotics are effective in the management of bacterial respiratory  
 
tract infections, leading to more rapid resolution of infection and relief of  
 
symptoms. They can also help prevent the progression of disease from acute to  
 
chronic manifestations.  
 
Antibiotic regimens are based on empiric knowledge of the common  
 
pathogens responsible for the disorder, predominantly Streptococcus  
 
pneumoniae, Haemophilus influenza, and Moraxella catrrhalis, and  
 
penicillin, amoxycillin, and ampicillin have been standard therapies in  
 
non-allergic patients. Other antimicrobials, including the cephalosporins,  
 
macrolides, sulpha-based antibiotics, and the fluoroquinolones, have been  
 
utilized in comparative studies over the years. Studies have documented  
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the prevalence of intermediate and resistant S.pneumoniae to  
 
penicillin over the past two decades. The resistance patterns have been a  
 
major concern for health care providers who used to depend on the  
 
susceptibility of the most common pathogens to penicillins. Bacteria  
 
develop resistance to penicillin by alteration of penicillin-binding  
 
proteins or by production of  beta-lactamase production has increased and  
 
remains at approximately 405 for H.influenza and at 98% for  
 
M.catarrhalis. Brook 2001; Brook and Frazier 2001; Brook 2004 note that  
 
beta-lactamase-producing bacteria can express their pathogenicity directly  
 
through their ability to cause infections and indirectly by production of  
 
enzymes. This protects penicillin-susceptible pathogens from penicillin  
 
failure in the management of group-A-beta haemolytic streptococcal  
 
tonsillitis. 
 
Overuse of antibiotics contribute to the resistance of microorganisms.  
 
Factors contributing to this include patient expectation, clinician time  
 
constraints, defensive medicine and avoiding the potential sequelae of not  
 
prescribing for a patient who has a bacterial infection. Studies in Finland  
 
showed that the consumption of erythromycin was related to an increase  
 
in the development of erythromycin-resistant group A streptococci. Yet,  
 
after 2 years a significant decline in macrolide-resistant group A  
 
streptococcus infection occurred after use of the macrolide antibiotics  
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was reduced. Klossek et al evaluated the types of  bacteria implicated in chronic  
 
rhinosinusitis. Endoscopic-guided cultures were performed. They found  
 
approximately 25% of isolates produced beta-lactamase, resulting in   
 
a decrease in sensitivity to penicillin in13% of isolates. Their findings  
 
showed that amoxycillin-clavulanate was the most active oral antibiotic  
 
in vitro.  
 
Over the past few years, developments in the evaluation of  
 
pharmacokinetics (absorption, distribution, metabolism and excretion) of  
 
antimicrobials has been established. Pharmacodynamics relates to the  
 
concentration of the drug and its pharmacologic effect.  Antimicrobials  
 
may exhibit either time-dependent killing or concentration-dependent  
 
killing. Time-dependent antimicrobials include the beta-lactams,  
 
macrolides, and clindamycin. Once these antibiotics reach a critical  
 
concentration, increasing the concentration further will not increase the  
 
rate or extend the bacterial killing.  Concentration- dependent antibiotics  
 
need to achieve the a relative value well above the minimal inhibitory  
 
concentration of the bacteria. It is necessary for these antimicrobials to  
 
obtain a very high peak of concentration and they are not time dependent.  
 
The most recent data are from The Anti-microbial Treatment Guidelines  
 
for acute bacterial rhinosinusitis is established by the Sinus and Health  
 
Partnership. Based on the efficacy rates, the partnership developed  
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recommendations for antimicrobial therapy. These recommendations were  
 
appropriate for patients with mild disease who had received antibiotics in the  
 
previous 4-6 weeks and patients with moderate disease  
 
assuming severe disease would require intravenous treatment. The  
 
recommended initial antibiotic therapy for adult patients or children with  
 
mild bacterial rhinosinusitis is amoxycillin-clavulanate, amoxycillin,  
 
cefodoxime, or cefuroxime, based on efficacy data. 
 
Treatment regimens suggest 10-14 days for adequate duration therapy in  
 
patients who develop  acute rhinosinusitis. Some have recommended an  
 
additional 7 days once symptoms improve. The duration of therapy  
 
remains unspecified as resistant bacteria can remain viable in a closed  
 
sinus long after effective antibiotic regimen has been in place. An initial  
 
2-4 week trial of antibiotics may be reasonable after surgical  
 
management for uncomplicated chronic infection. Invasion of bone or  
 
deep structures may require a prolonged antibiotic course. Amoxicillin  
 
interferes with synthesis of muco-peptides during active multiplications,  
 
resulting in bactericidal activity in susceptible bacteria.  
 
Clarithromycin inhibits bacterial growth, possibly by blocking peptidyl  
 
t-RNA from ribosomes, causing RNA-dependent protein synthesis. 
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7.4.17  Macrolides 
 
Studies of macrolides in chronic airways disease, such as diffuse  
 
pan-bronchiolitis (DPB) has led to improvements in pulmonary  
 
function (Banerjee, Khair et al. 2005). Similar benefits have been documented in  
 
Japanese studies of bronchiectasis, chronic bronchitis and sino-bronchial  
 
syndrome. Clinical and pathologic similarities between DPB and cystic fibrosis  
 
(CF) led to the investigation of macrolides for the treatment of CF. In vitro and in  
 
vivo studies of  macrolides suggest that they inhibit the pulmonary influx of  
 
neutrophils and release of pro-inflammatory cytokines. They also protect the  
 
epithelium from bio-active phospholipids, and improve the transportability of   
 
airway secretions (Kikuchi, Hagiwara et al. 2002; Kikuchi, Hagiwara et al. 2003).  
 
The immune-modulatory effects of the macrolides also may be beneficial for the  
 
treatment of other chronic inflammatory conditions. 
 
Interest in the immune-modulatory effects of macrolide antibiotics began  
 
with the observation that patients with severe asthma required lower doses  
 
of steroids if they also received troleanddomycin (TAO).  
As a primary anti-inflammatory activity, the macrolides appear to target nuclear 
transcriptional regulation. The stimulation of cells with various cytokines (e.g IL-8 
and TNF-α) induces and activates a number of nuclear-binding proteins, which in 
turn trigger the transcriptional process to initiate and amplify the inflammatory 
response. Nuclear factor-kappa B is a protein that is essential for the transcription 
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of genes that encode a number of pro-inflammatory molecules that participate in 
the acute inflammatory responses, including TNF-α, ICAM-1, inducible nitric 
oxide synthase (Inos), IL-6, and IL-8. NF-kappa B is composed of two proteins, 
p50 and p-65.  
The findings of studies by Ichiyama and colleagues concluded that macrolides 
modulate inflammatory activity in pulmonary epithelial cells and peripheral blood 
monocytes via a fundamental event or process. This quite possibly occurs at the 
level of gene cells and peripheral blood monocytes via a fundamental event at the 
level of gene transcription for pro-inflammatory cytokines. 
Subsequently macrolides have been studied for other airway diseases  
 
including diffuse pan-bronchioilitis (DPB) and cystic fibrosis (CF) (Martinez and  
 
Simon 2004).  Macrolides increase mucociliary clearance, improve sinusitis  
 
symptoms and decrease nasal secretions and polyp size in patients with sinusitis.  
 
They have also been shown to modify the inflammatory response  
 
associated with chronic sinusitis (Morikawa, Oseko et al. 1994). In patients  
 
with asthma, macrolides have been reported to reduce airway hyper-responsiveness  
 
and improve pulmonary function. They have been reported to reduce airway  
 
hyper-responsiveness as well as improving  pulmonary function, and have  
 
historically been selected for their “steroid-sparing” effect. Data form  
 
patients with COPD have shown improvements in symptom scores and  
 
FEV1 after macrolide treatment.  Macrolides, thereby, have the potential to  
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improve the outcomes of patients with inflammatory airways diseases.  
 
Large scale, placebo- controlled clinical trial in upper-respiratory  
 
inflammatory are warranted. Independent of their potent antimicrobial  
 
activity, 14-membered and 15-membered macrolides possess anti- 
 
inflammatory properties that may contribute to clinical benefits observed  
 
in patients with airway inflammation (Gotfried, M. H. (2004). "Macrolides for the  
 
treatment of chronic sinusitis, asthma, and COPD." Chest 125(2 Suppl): 52S-60S;  
 
quiz 60S-61S). 
 
A number of studies have shown an improvement in the clinical  
 
symptoms of corticosteroid-dependent patients with asthma and a  
 
reduction in the corticosteroid dosage with concomitant TAO therapy.  
 
Pharmacokinetic studies indicate this may be due, in part, to inhibition of  
 
steroid metabolism. TAO therapy was shown to significantly prolong the  
 
serum half-life of methylprednisolone. In some reported studies some  
 
steroid-dependent patients were able to completely discontinue  
 
concomitant oral steroid therapy without worsening asthma severity,  
 
suggesting that TAO has directly anti-inflammatory activities. 
 
Macrolide antibiotics also appear to be muco-regulatory, that is, they are  
 
able to decrease mucus hypersecretion in patients with airway disease  
 
without suppressing baseline physiologic secretions. Clarithromycin not  
 
only improves the solid composition of mucus but also reduces the  
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volume of nasal mucus secretion. Macrolides also affect neutrophil  
 
migration, the oxidative burst in phagocytes, the production of  
 
pro-inflammatory cytokines and eosinophilic inflammation. 
 
Macrolides and clinical experience 
 
Report of macrolide use in patients with chronic sinusitis come primarily  
 
from small, open-label case series. Consistent across the studies have  
 
been improvements in sinusitis symptoms, shrinkage in the size of  
 
nasal polyps, and a decrease in levels of pro-inflammatory cytokines in  
 
nasal secretions. Most of the clinical experiences demonstrating the  
 
favorable anti-inflammatory effects of macrolides on patients with  
 
chronic sinusitis have been published in the Japanese literature.  
 
Data from the beginning of the last decade by Kikuchi et al in Japan  
 
documented improvement of sinusitis signs and symptoms in 50 to 100%  
 
of patients who are given macrolide therapy. The investigators treated 26  
 
post-operative patients with persistent sinus symptoms following sinus  
 
surgery using erythromycin, 600mg per day for an average of 7.9 months. 
 
Also published in Japanese literature were the results of studies by Nishi  
 
et al and Suzuki et al. Following treatment with clarithromycin, 400mg  
 
daily for 4 weeks, significant improvements in mucociliary clearance,  
 
volume of secretions, cough frequency and dyspnoea-on-exertion were  
 
documented in 32 patients with sino-bronchial syndrome. Low-dose  
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roxithromycin (Rulid; Albert-Roussel Pharma GmbH; Wiesbaden,  
 
Germany) was shown to significantly improve the aeration of all four  
 
sinuses and to significantly reduce neutrophil and IL-8 levels in the nasal  
 
discharge of 12 patients with chronic sinusitis. 
 
The first article describing the use of macrolide in patients with chronic  
 
sinusitis appeared in the English literature in 1996. Hashiba and Baba  
 
treated 45 chronic sinusitis patients with clarithromycin, 400mg daily for  
 
8 to 12 weeks. Improvements in symptoms and rhinoscopic findings were  
 
directly related to the duration of macrolide therapy. The investigators  
 
improved rates of  therapy. Clinical benefit in patients with chronic  
 
sinusitis also was observed following long-term administration of  
 
roxithromycin. Patients with chronic sinusitis often develop nasal polyps,  
 
which are either neutrophil-dominant (i.e containing abundant  
 
pro-inflammatory cytokines such as IL-8) or eosinophil-dominant. The 14- 
 
member macrolides (e.g erythromycin, clarithromycin), inhibited IL-8  
 
secretion from cultures of human nasal epithelial cells harvested from the  
 
nasal polyps of patients with chronic sinusitis. 
 
Yamada et al evaluated the effect of macrolide therapy on size of nasal  
 
polyps and IL-8 levels in the nasal lavage fluid of 20 patients ( age range,  
 
24 to 84 years; mean age, 57 years) with chronic paranasal rhinosinsusits. All  
 
patients had experienced >1 year of symptoms. During macrolide treatment  
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patients had a significant decrease in IL-8 levels, a critical cytokine in the  
 
pathogensis of chronic rhinosinusitis. Clinical response correlated significantly  
 
with decreased IL-8 levels. In the group of patients in whom polyps were reduced  
 
in size during macrolide therapy, IL-8 levels were significantly higher at baseline  
 
and decreased by more than five-fold. In contrast, there was no difference in IL-8  
 
levels before and after macrolide therapy in patients in whom polyps did not  
 
change in size. The investigators theorized that the shrinkage of nasal  
 
polyps by macrolide is related to the suppression of cytokines production  
 
by inflammatory cells in the paranasal sinus epithelium. 
 
Low dose long term macrolide therapy may be one of the most exciting  
 
alternative treatments for CHES (Hashiba and Baba 1996). There are  
 
however no large-scale placebo-controlled clinical trials to confirm the results of  
 
several open-label trials. It must be noted that a recent study demonstrated the use  
 
of erythromycin by itself , and even further in combination with other drugs,  
 
significantly increases the risk of cardiac death, thereby raising concern  
 
about the recommendation for the routine use of this drug class. 
 
 
 
7.4.18   Novel Therapy 
 
Immunosuppressive therapy  
  
There are several new immune-modifying drugs that have yet to be formally  
 
studied in CHES. 
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Immune modulation 
 
Whilst traditional immunotherapy is clearly efficacious for allergic  
 
rhinitis, there have not been well-performed studies on CHES. Clinical  
 
trials are currently under way investigating methods of making  
 
immunotherapy safer and more effective. 
 
Immunomodulation holds promise for the future of CHES, but in light of  
 
their cost and possible side effects they need to be better studied before  
 
being implemented in the clinical setting. 
 
Environmental factors or allergic factors in these patients may be amenable to the  
 
following preventative measures: 
 
- Reduce exposure to dust, moulds, cigarette smoke and other  
 
environmental chemical irritants. 
 
- Environmental control, antihistamines, cromolyn, topical steroids  
 
or immunotherapy may be helpful in the medical management. 
 
7.4.19    Complications 
 
1 Orbital cellulitis 
 
2 Cavernous sinus thrombosis 
 
3 Intracranial extension (e.g, brain abscess, meningitis) 
 
4 Mucocele formation 
 
7.4.20    Prognosis 
 
Satisfactory outcomes result when a patient with chronic sinusitis is  
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treated with aggressive medication. Functional endoscopic sinus surgery  
 
restores sinus health with complete or moderate relief of symptoms in 80- 
 
90% of patients.  
 
It must be noted that nasal swab cultures do not correlate with sinus  
 
culture results. Always consider serious underlying conditions such as  
 
neoplasms and immunodeficiency states. Fungal sinusitis can be devastating  
 
in immunosuppressed patients. 
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8.  HYPOTHESIS AND OBJECTIVES 
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8.1 Hypothesis 
 
Rhinitis is an inflammatory condition affects the nasal mucosa. 
 
The complex pathophysiology results in an often poorly understood  
 
condition. An overlap in symptoms of allergic rhinitis and chronic rhinosinusitis  
 
renders early diagnosis difficult. Management often is poor and consequently  
 
patients are often left feeling abandoned by their clinician. 
 
The aims of this study are to further our understanding of the potential  
 
differences in the pathophysiological mechanisms of the two conditions  
 
and their interactions with macrolides whose function is complex. 
 
1. My first hypothesis is that there are fundamental differences in baseline  
 
immunomodulatory activity between chronic rhinosinusitis and allergic  
 
rhinitis. The study aims to identify activity of specific cytokines, IL-6 and  
 
IL-8, both of which are already known to contribute to pathways of intra- 
 
cellular activity in each condition. 
 
2. My second hypothesis is that macrolides influence activity of IL-6 and IL-8  
 
in chronic rhinosinusitis and allergic rhinosinusitis and that there are  
 
differences in cytokine responses within each condition. ‘Macrolide – 
 
generated’immunomodulatory  responses can have significant implications  
 
in the future treatment of these conditions. 
 
The effects of macrolides on each group may help to formulate an improved  
 
understanding of these mechanisms and thereby determine 
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whether application in their treatment may  benefit one or more 
 
specific group of patients. 
 
 
8.2 Objectives 
 
The objectives of this study are: 
 
1. To culture HNECs as primary cultures from nasal turbinate  
 
biopsies. 
 
2. To compare the constitutive release of two inflammatory  
 
markers (IL-6, IL-8) from well characterized non-atopic  
 
non-rhinitic subjects (Normal subjects); subjects with active  
 
perennial allergic rhinitis (Rhinitics); and  non-atopic  
 
chronic rhinosinusitics. 
 
3. To compare the quantity of IL-6, IL-8 released by HNECs    
 
obtained from well characterized Normal subjects, Rhinitics,  
 
Chronic Rhinosinusitics following exposure to Bacterial  
 
endotoxin (LPS), macrolides and both LPS and  macrolides   
 
for a period of 24hours. 
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9.0 METHODS 
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9.1 METHODS 
 
Studies have shown that airway epithelial cells and cell lines are capable of  
 
Expressing and synthesizing a large variety of cytokines including interleukins, 
granulocyte macrophage-colony stimulating factor and tumour necrosis factor-α. 
These can either directly or in conjunction with one another influence growth, 
differentiation, migration and activation of eosinophils, neutrophils, mast cells, 
macrophages and lymphocytes. Epithelial cells in atopic and non-atopic 
individuals are thought to synthesize different amounts and a variety of profiles of 
cytokines 
 
 9.2 Nasal Biopsy  
 
Written consent was obtained from each patient prior to the procedure and  
 
a single nasal biopsy was taken from each patient. 
 
Nasal biopsies were obtained from the anterior end of the inferior  
 
turbinate, using a technique described by Prior (Prior et al, 1995). The  
 
inferior turbinate was decongested and anaesthetized by the application of  
 
a pledget of cotton wool soaked in 0.5-0.75 ml of 10% cocaine  
 
hydrchloride sterile solution. The pledget was placed between the inferior  
 
turbinate and the septum for ten minutes. A biopsy specimen of  
 
approximately 2-3mm3  in size was removed from each individual using  
 
cup biopsy specimen was immediately placed in ice-cold Medium 199 
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 containing a 1.5% (v/v) antibiotic/antimycotic additive. Each biopsy  
 
was processed for tissue culture. 
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Fig.13                       Human nasal epithelial cell culture  
 
                                           
 
 
Fig.14                                  Laboratory Incubator 
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9.3 Culture of human nasal epithelial cells (HNEC’s) 
 
9.3.1 Culture Media 
 
A number of specially prepared media were used during the culture of 
 
HNECs. A description of these media ensues: 
 
1. Media 199 plus 1.5% (v/v) antibiotic/antimycotic 
 
This solution contained Medium 199 ( Northumbria Biological Ltd) plus  
 
10,000 units/ml penicillin; 10mg/ml streptomycin and 25µg/ml  
 
amphotericin B (Sigma Chemicals, UK). This solution was used for  
 
transporting and washing the biopsy specimens prior to culture. 
 
2. Complete Medium 199 
 
This was prepared in 500ml aliquots. It consisted of 12.5ml foetal calf  
 
serum (Becton Dickinson Ltd, Oxford, UK); 5 ml bovine pancreatic  
 
insulin (2.5µg/ml); 5ml L-glutamine (0.02mg/ml);150µl epidermal  
 
growth factor (20ng/ml) and 7.5ml antibiotic/antimycotic solution made  
 
up to a final volume of 500ml with Medium 199. This solution was  
 
sterilized by filtration through a 0.20µm syringe filter (Sartorius,  
 
Milistart, UK) and was used for the culturing of cells during the first 5  
 
days. 
 
 
3. Maintenance Medium 199 
 
Maintenance Medium 199 was prepared as described above, however  
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foetal calf serum was replaced by 12.5ml Nu-Serum IV 2.5% (Universal  
 
Biologicals Ltd, UK). This medium was used to sustain the cell culture 
 
subsequent to the first 5 days and was changed 3 times weekly  
 
there-after. 
 
9.3.2 Culture Technique 
 
HNECs were grown from the biopsy specimens as explant culture, using  
 
the technique described by Steele & Arnold and modified by Devalia  
 
(Steele and Arnold 1985; Gotfried 2004) ( Devalia, J. L., R. J. Sapsford, et al. 
(1990). "Culture and comparison of human bronchial and nasal epithelial cells in 
vitro." Respir Med 84(4): 303-12). 
The epithelium from each biopsy specimen was carefully dissected away  
 
from the underlying lamina propria using a dissecting microscope and cut  
 
into smaller sections approximately 1-2mm3 in size.  
 
All sections were washed 3 times in pre-warmed Medium 199 containing  
 
1.5% (v/v) antibiotic/antimycotic solution prior to explantation. Single 
 
 sections of epithelium were explanted onto 6cm diameter Falcon  
 
Primaria culture dishes (Becton Dickinson Ltd, Oxford, UK) with 1.5ml  
 
of Complete Medium 199.  
 
The culture dishes were incubated at 370C in a 5% CO2 in air atmosphere  
 
at 80-90% humidity (Incubator model Sherlab TC2323). After 5 days  
 
incubation in complete Medium 199 the medium was replaced with  
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Maintenance Medium 199 which was changed 3 times weekly thereafter. 
 
The HNECs were allowed to grow to confluence, a process taking 3-4  
 
weeks on average. Once confluence had been attained the explants were 
 
removed from the culture dishes and the epithelial cell cultures washed  
 
gently with 2mls of freshly prepared Maintenance Medium 199. A further 
 
week of incubation was allowed for the epithelial cell cultures to  
 
overgrow the area left by the removed explant.  
 
9.3.3  Confirmation of epithelial cell identity 
 
9.3.3.1 Light microscopy 
 
All HNEC cultures were examined by phase contrast light microscopy  
 
using an Olympus IMT-2 inverted microscope (Olympus Optical, UK),  
 
modified with the Hoffman modulation contrast optical system  
 
(Modulation Optics Inc, Greenvale, NY, USA). This allowed a detailed 3-D  
 
visualisation of the topographical features of the cells and confirmation  
 
of epithelial cell identity.  
 
 
9.4 Exposure of HNECs to LPS and Macrolides. 
 
9.4.1 Method 
 
24 hours prior to exposure the HNEC Maintenance Medium 199 was  
 
carefully removed with a pipette and replaced by 2mls of Medium 199  
 
plus macrolide plus 1.5% (v/v) antibiotic/antimycotic. 
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Thirty minutes prior to exposure the HNECs were gently washed 2 times  
 
with Medium 199 plus 1.5% (v/v) antibiotic/antimycotic, in order to  
 
remove any cytokines generated overnight. Two millimeters of Medium  
 
199 plus 1.5% (v/v) antibiotic/antimycotic were then placed in each dish  
 
in order to bathe the cells during the experiment. 
 
HNECs from each patient within the 3 groups were further sub-grouped 
 
according to exposure of sample: 
 
1 Control (C) 
 
2 LPS Endotoxin (L) 
 
3 Macrolide- Erythromycin (M) 
 
4 LPS and Macrolide (LM) 
 
9.4.2  Controls 
 
These HNEC’s were not exposed to either macrolide or endotoxin and  
 
were assayed to obtain a baseline levels of IL-6 and IL-8 for each patient. 
 
9.4.3 LPS  
 
LPS endotoxin was prepared from E.Coli endotoxin concentrate by routine  
 
methods as applied by Khair, Devalia et al. 1994; Khair, Devalia et al. 1995;  
 
Khair, Davies et al. 1996. This enabled evaluation of the effect of macrolide  
 
exposure to bacterial endotoxin-stimulated HNECs in all three patient  
 
groups. 
 
Prior to cytokine measurement the HNECs were placed into the main  
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Sherlab incubator for a 24 hours. Once the 24hours had elapsed the culture  
 
medium was siphoned off using a pipette and stored at -700C until analysed  
 
for IL-6,and IL-8. The adherent cells were scraped from the culture dish;  
 
collected in 1ml of Medium 199 and stored at -700C until analysed for total  
 
cellular protein. 
 
 
9.4.4  Macrolides 
 
The confluently cultured human nasal epithelial cells were incubated with 
 
10-5 macrolide  (Miyanohara, Ushikai et al. 2000) for 24 hours. The cells were  
 
removed from tissue culture plate and used for evaluation of protein concentration. 
 
Sets of at least six separate cultures for each specimen were sub-grouped  
 
and incubated at 370C in 5% CO2 in air atmosphere for 24hrs. The effect  
 
of each treatment regimen was investigated on the same day. At the end  
 
of  incubation, the medium from each culture was stored at  -700C until  
 
analysis for IL-6 and IL-8 using commercially available enzyme-linked  
 
immunosorbent assay (ELISA) kits(British Biotechnology Ltd,  
 
Abingdon, UK). The cells in each culture were collected for protein  
 
analysis and the results for the mediators released by HNEC’s were  
 
expressed as pg.µg-1 cellular protein.  
 
In order to determine whether or not release of cytokines in HNEC’s is 
 
affected by endotoxin or macrolides,  at the end of each incubation 
 
period, the medium and cells were collected and analysed for IL-6 and 
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IL-8 total cellular protein as previously described. 
 
The concentration of each mediator present in the medium at the end of  
 
incubation was assessed by ELISA ( enzyme-linked immunoassay) as  
 
mentioned earlier. 
 
9.5 Cytokine measurement 
 
9.5.1   Method 
 
Culture media stored at –700C were allowed to thaw completely prior to 
 
Cytokine measurement. The analysis for IL-6 and IL-8 was carried out  
 
using commercially available ELISA kits, which were used according to  
 
the manufacturer’s instructions (R&D Systems, Abingdon,UK). These 
 
assay kits were highly reproducible, specific and sensitive, with no  
 
significant cross reactivity or interference between the 3 cytokines  
 
investigated. Results for IL-6 and IL-8 were given as pg/ml. 
 
In order to account for differences in the number of cytokine producing 
 
cells in each culture dish, analysis of the total cellular protein was 
 
performed, and cytokine production was therefore expressed as pg of 
 
cytokine per µg of cellular protein. 
 
 
9.6 Measurement of cellular protein 
 
9.6.1 Method 
 
Measurement of total cellular protein was performed using a modified Lowry  
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method  (Lowry et al, 1951). The technique involved the treatment 
 
of  proteins with a copper reagent, which reacted with phenolic amino 
 
acids to produce a blue colour. The blue colour was then measured  
 
spectrophotometrically. 
 
The reagent used were as follows: 
 
Reagent A: 2% Sodium carbonate in 0.1M NaOH 
 
Reagent B: 0.5% Copper sulphate in 1% sodium potassium tartrate 
 
Reagent C: 100 parts of Reagent A: 2 parts of Reagent B 
 
Reagent D: Folin’s and Ciocalteau’s phenol reagent diluted 1.5 times with  
 
distilled water 
 
100µl of cellular protein sample was made up to 500µl with 0.15M Saline  
 
solution. 2.5 ml of  Reagent C was added to each sample using a vortex mixer and  
 
allowed to stand for 10 minutes at room temperature. 
 
0.25 ml of Reagent D was the added and mixed immediately and allowed 
 
to stand at room temperature for 30 minutes. This reaction resulted in a  
 
blue solution which was measured spectrophotometrically at an  
 
absorbance value of 758nm, in a Cecil Model CE 292 UV Spectrophotometer  
 
(Cecil, Cambridge,UK). This method was capable of detecting total protein  
 
concentrations as low as 2µg absolute. The amount of cellular protein per sample  
 
was determined from a protein standard curve prepared using serial dilutions of  
 
crystalline bovine serum albumin ranging from 0-100 mg/assay. Fresh standards  
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were prepared for each experiment. 
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10    EXPERIMENTS 
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10.1 Ethics approval 
 
Full ethics approval for this study was obtained from the East London and  
 
City Health Authority Research Ethics Committee. Study No. P/99/194. 
 
 
10.2 Subject selection 
 
A total of 43 patients were recruited into the study. Subjects were 
 
characterized into one of three groups. 
 
The groups were as follows: 
 
“Normal subjects”  (n=15) 
 
“Allergic rhinitics” (n=12) 
 
“Chronic rhinosinusitics” (n=21) 
 
Patients were initially assessed in the ENT Outpatient clinic at  
 
St.Bartholomew’s Hospital, London. 
 
All subjects were: 
 
1 Over 18 years of age. 
 
2   Not taking any anti-allergy medication (within the previous 8 weeks). 
 
3 Not taking any medical treatment known to cause rhinitis. 
 
4 Non-pregnant. 
 
 
10.3 Characterisation of Normal subjects. 
 
History- Normal subject had no medical history of atopic or respiratory  
 
disease including rhinitis, asthma or COPD. All selected were non-smokers. 
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Examination- No evidence of rhintis, asthma or COPD. 
 
Investigations- All subjects were deemed to have normal lung function as  
 
measured by spirometry and to be non-atopic as evinced by prick testing. 
 
Spirometric measurements were taken under my supervision using a  
 
Micro Spirometer. (Micro Medical Ltd, Rochester, UK). Normal values  
 
were taken to be FEV1> 70% PREDICTED AND FEV1/FVC ratio >  
 
70%. 
 
The skin prick testing technique is described in 8.3.4.1 
 
10.4 Characterisation of Rhinitics subjects 
 
History- Rhinitic subjects had a positive history for rhinitis as defined by  
 
the International Rhinitis Management Working Group (Lund et al,  
 
1994). This requires a minimum of two of the following symptoms for >  
 
1 hour a day on most days. 
 
1. Nasal discharge 
 
2. Nasal blockage 
 
3. Sneeze / Itch 
 
In order to ensure a significant burden of disease in the study patients, the  
 
afore- mentioned symptoms must have been present for more than 6 months. 
 
There was no medical history of respiratory disease including asthma or  
 
COPD. All Rhinitic subjects were life-long non-smokers. 
 
Examination- No evidence of asthma or COPD. 
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Investigations- All Rhinitic subjects in this study were skin prick test  
 
positive to house dust mite allergen only. 
 
All subjects were deemed to have normal lung function as measured by  
 
spirometry. 
 
Spirometric measurements were taken under my supervision using a  
 
Micro Spirometer. Normal values were taken to be FEV1>70% predicted  
 
and FEV1/FVC ratio> 70%. 
 
 
10.4.1 Skin prick allergy testing . 
 
Prior to skin testing verbal consent was sought from all patients. Patients  
 
were asked about precluding factors for skin prick testing, including a  
 
history of severe allergic reactions, anaphylaxis, significant eczema or  
 
dermographism. All 43 patients gave their consent and there were no  
 
precluding factors. 
 
Test substances used were Soluprick SQ allergen extracts, provided by  
 
ALK-Abelló lancet was used to pierce the skin. The lancet is designed to  
 
allow penetration of approximately 5ηl of fluid into the subcutaneous  
 
layer. 
 
The test substances used in this study were:- 
 
1. Negative control (Saline) 
 
2. Positive control 
 
3. House dust mite (Dermatophagosides pteronyssinus) 
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4. Five grass mix (Timothy grass, Rye grass, Perennial rye, Meadow  
 
fescue, Bermuda grass). 
 
5.  Four tree mix (Birsch, Alder, Hazel, Hornbeam) 
 
6. Mould (Aspergillus Fumigatus) 
 
7. Dog (Cnais familiaris) 
 
8. Cat (Felix domesticus) 
 
Wheals with a diameter 3mm greater than the negative control, with  
 
associated flare and itching were considered as a positive skin prick test  
 
reaction. 
 
 
 
 
 
 
 
Fig.15     Fig.16 
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10.5   Characterisation of Chronic Rhinosinusitic Patients 
 
21 patients with duration of more than 3 months of symptoms compatible  
 
with Chronic Rhinosinusitis were recruited to the study group. All patients  
 
were ‘skin-prick test’ negative. Symptoms included prolonged nasal congestion or  
 
obstruction, thick green-yellowish rhinorrhoea, postnasal drip, anosmia, malaise,  
 
attacks of headache, facial pain and discomfort or pressure in the regions of the  
 
sinuses. The patients were scheduled for functional endoscopic sinus surgery  
 
(FESS) because of insufficient clinical response to repeated antibiotics,  
 
mucolytics, antihistamines, decongestants and intranasal steroid sprays. 
 
                                                                                                                                                                
10.6 Statistical analysis 
 
Statistical analysis was carried out using the computer based analysis  
 
program SPSS 15(Statistical Package for Social Science, for PC,  
 
SPSS Inc, Chicago IL, USA). 
 
Kolmogorov- Smirnov analysis was used as a test of normality. The  
 
Wilcoxon Signed Ranks test was used to compare related samples and the  
 
Mann- Whitney test was used to compare independent samples. P values  
 
<0.05 were considered to be statistically significant. 
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11. RESULTS  
 
The effects of 24 hours exposure to LPS endotoxin, Erythromycin and a  
 
combination of both on human epithelial cells cultured from Normal  
 
subjects, Allergic Rhinitics and Chronic Rhinosinusitics. 
 
  11.1                  Clinical details of subjects 
 
 Nasal epithelial cells (HNECs) were cultured from Normal subjects, 
 
 Allergic Rhinitics and Rhinosinusitics. Individual clinical details for each  
 
 group are presented below.                            
 
 
 Table 1. 
 
Clinical details of Allergic Rhinitic Subjects (n=12) 
 
                                          
Group Sex Age/ yrs Height         
cm 
Weight 
 
BMI 
kg/m2 
FEV1      FVC         PEFR 
   l               l             l/min     
A1 M 30 167 85 30.5 3.2      3.26          595 
A2 F 34 173 72 24.1 3.43      3.65          430 
A3 F 23 165 75 27.6 2.11      2.73          470 
A4 M 19 165 72 26.5 2.65      2.81          565 
A5 F 20 170 56 25.5 3.6      3.6            435 
A6 M 24 162 68 24.5 4.08      4.4            590 
A7 M 28 167 85 30.5 3.2      3.26          610             
A8 F 34 170 61 21.1 2.66      2.66          430 
A9 M 40 161 90 34.5 2.65      2.65          580 
A10 M 33 152 67 28.5 2.7      2.9            615 
AR11 M 34 169 70 24.5 4.31      4.31          590 
AR12 F 26 152   60           25.5 2.87     3.17           432 
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Table 2 
     
                    Clinical details of Normal Subjects (n=15) 
  
  
Group Sex Age(yrs) 
 
Height(cm)
 
Weight(kg)
  BMI        
(kg/m2)     FEV1(l)
              
FVC(l) 
                 
PEFR       
( l/min) 
N1 M 31 164 58       21.6 0.21 0.21 610 
N2 F 22 154 45       19.0 2.49 2.49 410 
N3 M 26 173 65       21.7 3.2 3.20 614 
N4 M 25 167 68      24.4 4.61 5.01 665 
N5 M 22 167 61         21.5 3.4 3.40 630 
N6 M 33 167 85         30.5 2.99 3.18 610 
N7 M 33 161 68         24.5 4.21 4.21 614 
N8 F 28 154 54         22.5 3.23 3.40 590 
N9 F 20 167 104         37.5 3.09 3.10 430 
N10 M 23             171 80         27.5 3.27 3.40 590 
N11 M 40 160 87         33.5 3.24 4.03 614 
N12 F 18 155 60         24.5 2.57 2.57 460 
N13 M 24 167 85         30.5        4.0 4.32 605 
N14 M 37 174 83         27.5          3.01          3.12 625 
N15 M 36 174 90.5         29.5          3.23          2.67 630 
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Table 3 
 
 Clinical details of Chronic Rhinosinusitics (n=21) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Sex Age(yrs) Height(cm) Weight(kg)
    BMI 
(kg/m2)     FEV1(l)     FVC(l) 
 PEFR   
(l/min) 
CRS1 M 65 171 98      33.5 3.56 3.56 530
CRS2 M 54 171 72.5      24.5 2.62 2.62 545
CRS3 F 36 164 87      32.5 2.76 2.98 430
CRS4 F 39 154 58      24.5 2.04 2.08 448
CRS5 F 29 163 57      21.5 2.38 2.40 450
CRS6 F 42 155 73      30.4 3.19 3.32 630
CRS7 M 38 175 87      28.5 2.04 2.04 570
CRS8 M 56 172 71      24.5 3.08 3.09 580
CRS9 M 54 171 72      24.5 3.32 3.32 450
CRS10 F 45 159 70      27.5 2.1 2.10 424
CRS11 F 63 161 98      37.5 1.73 1.73 450
CRS12 F 55 160 68      26.5 2.92 2.98 455
CRS13 F 45 162 99      37.5 1.88 1.88 612
CRS14 M 43 159 85      33.5 1.1 1.10 630
CRS15 M 41 167 86      30.5 3.3 3.08 594
CRS16 F 46 161 65      25.1 2.17 2.21 620
CRS17 M 50 167 63      22.5 3.24 3.24 604
CRS18 M 40 169 101      35.5 2.64 3.05 454
CRS 19 M 51 170 74      25.5          3.19          3.22 615
CRS20 F 32 167 90      32.5          3.52          3.61           416
CRS21 M 41 180 80      24.5        3.27        3.40        517 
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Table 4   
 
A comparison of the log10 cellular protein concentration of Il-6 and IL-8  
 
in pre- and post stimulated epithelial cells in ‘Normal’ patients (pg/ml) 
 
                            
                                         
 
    
IL6 control IL8 control 
IL6 
macrolide 
IL8 
macrolide 
IL6 
Stimulated 
IL8 
Stimulated 
IL6 
Stimulated 
and 
Macrolide  
IL8 
Stimulated 
and 
Macrolide 
0.65 0.87 0.81 1.24 1.11 1.27 0.56 0.66
0.51 1.15 0.34 0.96 1.06 1.29 0.81 0.77
0.56 1.06 0.69 0.86 1.07 1.31 0.71 0.59
0.71 1.1 0.86 1.09 1 1.35 0.8 0.83
0.51 0.92 0.66 0.96 0.96 1.09 0.68 0.92
0.38 0.9 0.11 0.86 1 0.87 0.83 0.67
0.49 0.89 0.46 0.75 1.05 0.75 0.46 0.54
0.64 1.02 0.51 0.97 1.16 0.66 0.49 0.73
0.43 0.79 0.96 0.72 1.21 1.06 0.72 0.69
0.69 1.06 0.18 0.83 1.02 0.92 0.67 0.57
0.43 0.72 0.36 0.71 1.12 0.76 0.69 0.63
0.66 0.93 0.54 0.68 1.28 0.68 0.46 0.66
0.75 0.98 1.07 0.85 1.07 0.73 0.63 0.54
0.51 0.73 0.45 0.67 1.15 0.91 0.72 0.8
0.62 0.8 0.49 0.77 0.83 0.72 0.58 0.53
             
MEAN 0.56 0.92 0.57 0.86 1.07 0.96 0.64 0.68
S.D 0.15 0.13 0.28 0.16 0.11 0.25 0.12 0.12
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Table 5  
 
A comparison of the log10 cellular protein concentration of  Il-6 and IL-8  
 
in pre- and post stimulated epithelial cells in ‘Chronic Rhinosinusitic’  
 
patients (pg/µg cellular protein) 
 
 
MEAN 0.77 1.12 0.53 0.91 0.91 1.09 1.12 1.17
S.D 0.11 1.12 0.2 0.16 0.18 0.15 0.11 0.09
 
 
                               
IL6 control IL8 control 
IL6 
macrolide 
IL8 
macrolide 
IL6 
Stimulated 
IL8 
Stimulated 
IL6 
Stimulated 
and 
Macrolide  
IL8 
Stimulated 
and 
Macrolide 
0.65 1.35 0.38 1.21 1.29 1.18 1.13 1.21
0.88 1.1 0.72 0.88 1 1.13 1.05 1.16
0.91 1.1 0.87 1.11 0.97 1.26 1.26 1.05
0.76 1.33 0.54 0.88 0.91 0.8 0.92 1.12
0.91 1.03 0.41 0.86 0.69 0.76 0.88 1.05
0.62 0.93 0.57 0.61 0.97 0.86 0.96 1.06
0.68 1.26 0.58 0.85 0.86 0.91 1 1.24
0.81 1.17 0.76 0.95 0.91 0.97 1.09 1.11
0.79 0.94 0.51 0.87 0.85 1 1.12 1.27
0.86 1.09 0.39 0.79 0.88 1.05 1.27 1.18
0.57 0.81 0.49 0.76 0.68 1.11 1.18 1.28
0.73 1.12 0.38 0.77 0.72 1.03 1.09 1.06
0.92 1.36 0.54 0.93 0.97 1.22 1.29 1.3
0.89 1.27 0.15 0.88 0.91 1.27 1.13 1.23
0.86 1.06 0.88 1.05 0.8 1.23 1.22 1.24
0.81 1 0.52 0.66 0.86 1.14 1.19 1.14
0.69 1.11 0.41 0.77 0.79 1.15 1.09 1.28
0.87 1.05 0.38 1.18 0.54 1.25 1.18 1.06
0.67 0.93 0.65 1.14 1.26 1.13 1.26 1.29
0.6 1.21 0.18 1.01 1.09 1.13 1.15 1.16
0.76 1.26 0.79 0.93 1.12 1.21 1.09 1.15
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Table 6 
 
A comparison of the log10 cellular protein concentrations  of  Il-6 and IL-8  
 
in pre- and post stimulated epithelial cells in ‘Allergic Rhinitic’  
 
patients (pg/µg cellular protein) 
 
 
 
MEAN 0.66 0.73 0.39 0.5 0.73 1.01 0.6 0.68
S.D 0.11 0.97 0.16 0.12 0.07 0.28 0.14 0.1
 
 
 
 
 
 
 
 
 
                                     
IL6 
control IL8 control 
IL6 
macrolide 
IL8 
macrolide 
IL6 
Stimulated 
IL8 
Stimulated 
IL6 
Stimulated 
and 
Macrolide  
IL8 
Stimulated 
and 
Macrolide 
0.63 0.89 0.42 0.58 0.72 0.79 0.38 0.51
0.58 0.73 0.56 0.35 0.67 1.43 0.57 0.65
0.75 0.75 0.37 0.63 0.77 0.85 0.45 0.85
0.42 0.86 0 0.26 0.71 0.86 0.54 0.63
0.88 0.66 0.48 0.51 0.87 1.12 0.58 0.64
0.77 0.58 0.44 0.53 0.78 0.7 0.85 0.88
0.71 0.81 0.51 0.57 0.7 0.83 0.51 0.72
0.59 0.71 0.33 0.67 0.62 1.37 0.65 0.72
0.7 0.68 0.27 0.41 0.72 0.63 0.63 0.68
0.61 0.64 0.34 0.5 0.72 1.26 0.79 0.62
0.65 0.79 0.58 0.53 0.65 1.33 0.53 0.59
0.66 0.62 0.42 0.41 0.84 1 0.76 0.68
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 11.2                                INTERGROUP STATISTICS 
 
The results below compare the baseline interleukin activity within the three patient  
 
groups. Levels of IL-6 were significantly higher in unstimulated Allergic Rhinitics  
 
in comparison with Normal patients (p=0.04). IL-8, however, is lower in Allergics  
 
than Normals with Chronic Rhinosinusitics showing the highest levels of activity    
 
(p=0.001). 
 
This is shown below in tables 7 and 8. 
 
Baseline levels of IL-6 and IL-8 in un-stimulated Allergic and Normal Patients  
 
(pg/µg cellular protein) 
 
Table 7  
          
   GROUP N Mean 
Std. 
Deviation
Std. 
Error 
Mean 
Unstimulated Allergic   12 0.66 0.12 0.03
IL6 Normal 15 0.57 0.11 0.03
Unstimulated Allergic   12 0.73 0.1 0.03
IL8 Normal 15 0.92 0.14 0.04
 
 
 
Table 8  
 
                                                  Independent Samples Test 
 
                    t-test for Equality of Means 
  
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference
95% Confidence 
Interval of the 
Difference   
        Lower Upper   
Unstimulated 
IL6 
Equal 
variances 
assumed 0.044 0.09 0.04 0.002 0.19   
Unstimulated 
IL8 
Equal 
variances 
assumed 0.001 -0.2 0.05 -0.3 -0.1   
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Macrolides lower IL-6 and IL-8 in unstimulated HNEC’s in all three groups  
 
however the response is more prevalent in AR (tables 11-16). 
 
Effect of macrolides on baseline levels of IL-6 in Allergic and Normal Patients  
 
(pg/µg cellular protein) 
 
 
 
 
Table 9                          Group Statistics 
 
 
  GROUP N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Control 
IL6 
Allergic 12 0.66 0.11 0.03 
Normal 15 0.57 0.11 0.03 
Macrolide 
IL6 
Allergic 12 0.39 0.16 0.05 
Normal 15 0.57 0.28 0.07 
 
 
 
  
  Table 10                                 Independent Samples Test 
 
 
                    t-test for Equality of Means 
  
Sig. 
(2-
tailed)
Mean 
Difference
Std. Error 
Difference
95% 
Confidence 
Interval of 
the 
Difference   
        Lower Upper   
Control 
IL6 
Equal 
variances 
assumed 0.044 0.09 0.04 0.003 0.19   
Macrolides 
IL6 
Equal 
variances 
assumed 0.064 -0.17 0.09 -0.36 0.01   
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The effect of macrolides on IL-8 in pre and post stimulated cells of Allergic  
 
and Normal patients (pg/µg cellular protein)  
 
                            Table 11 
 
     
 
 
 
 
                                Table 12 
  
Equal 
variances 
assumed Sig. 
(2-
tailed)
Mean 
Difference
Std. Error 
Difference
95% 
Confidence 
Interval of the 
Difference 
   Lower Upper 
Control 
IL8   0.001 -0.2 0.05 -0.29 -1 
Macrolides IL8 0.001 -0.37 0.06 -0.48 -0.25 
Stimulated  IL8 0.5 0.06 0.1 -0.15 0.27 
Stimulated and 
Macrolides IL8 0.91 0.01 0.04 -0.08 0.09 
 
 
 
 
 
 
 
 
  GROUP N Mean 
Std. 
Deviation
Std. 
Error 
Mean 
Unstimulated 
IL8 
Allergics 12 0.73 0.1 0.03 
Normals 15 0.92 0.14 0.04 
Macrolide 
IL8 
Allergics 12 0.5 0.12 0.03 
Normals 15 0.86 0.16 0.04 
Stimulated 
IL8 
Allergics 12 1.01 0.28 0.08 
Normals 15 0.96 0.25 0.06 
Stimulated 
and 
macrolide 
IL8 
Allergics 12 0.68 0.10 0.03 
Normals 
15 0.68 0.12 0.03 
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Effect of macrolides on baseline levels of IL-6 in Chronic Rhinosinusitics and  
 
Normal patients(pg/µg cellular protein) 
 
 
Table 13  
 GROUP N Mean 
Std. 
Deviation 
Std. Error 
Mean 
IL6 Unstimulated CRS 21 0.78 0.11 0.02 
  Normal 15 0.57 0.11 0.029 
IL6 Stimulated        CRS 21 0.91 0.18 0.04 
     Normal 15 1.1 0.11 0.028 
IL6 Stimulated and macrolide CRS 21 1.12 0.11 0.025 
     Normal 15 0.65 0.12 0.03 
 
            Table 14                        
 Independent Samples Test 
 
  t-test for Equality of Means 
  
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
        Lower Upper 
IL6 
Unstimulat
ed 
Equal 
variances 
assumed 
0.001 0.21 0.04 0.13 0.28 
IL6 
Stimulated 
Equal 
variances 
assumed 
.004 -0.17 0.05 -0.28 -0.06 
IL6 
Stimulated 
and 
macrolides 
Equal 
variances 
assumed 0.001 0.47 0.04 0.39 0.55 
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Effect of macrolides on baseline levels of IL-8 in Chronic Rhinosinusitics and  
 
Normal patients (pg/µg cellular protein) 
 
  Table 15 
 GROUP N Mean 
Std. 
Deviatio
n 
Std. Error 
Mean 
IL8 Unstimulated CRS 21 0.91 0.16 0.04 
  Normal 15 0.86 0.16 0.04 
IL8 Stimulated CRS 21 1.1 0.15 0.03 
  Normal 15 0.96 0.25 0.06 
IL8 Stimulated and macrolide CRS 21 1.17         0.09 0.02 
  Normal 15 0.68 0.12 0.03 
 
 
  
              Table 16   
 
                                                         Independent Samples Test 
 
  t-test for Equality of Means 
  
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
        Lower Upper 
IL8 Unstimulated Equal 
variances 
assumed 
0.39 .048 0.06 -0.06 0.16
IL8 Stimulated Equal 
variances 
assumed 
0.06 0.13 0.07 -.008 0.26
IL8 Stimulated and 
macrolides 
Equal 
variances 
assumed 
0.001 0.5 0.03 0.42 0.57
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11.3                             INTRA-GROUP ANALYSIS 
11.3.1  Normals 
 
• Baseline IL-6 levels are lower than AR and CRS (p=0.04) 
• Baseline IL-8 levels are lower than CRS but not AR (p=0.001) 
• LPS raises IL-6 (p=0.001) and mildly raises IL-8 (p=0.57) 
• Macrolides markedly lower IL-6 (p=0.001) and IL-8 (p=0.001) in stimulated 
cells 
 
A comparison of the effect of macrolides on stimulated and unstimulated IL6 
and IL-8 in Normal patients (pg/µg cellular protein) 
 
 
 
                      Paired Samples Statistics 
 
Table 17 
 
Mean N 
Std. 
Deviation 
Std. Error 
Mean 
Pair 1 IL6 Control 0.5684 15 0.11387 0.0294 
IL6 Stimulated 1.0729 15 0.10887 0.02811 
Pair 2 IL8 Control 0.922 15 0.13882 0.03584 
IL8 Stimulated 0.9584 15 0.25015 0.06459 
Pair 3 IL6 Stimulated 1.0729 15 0.10887 0.02811 
IL6 Stimulated and 
macrolide 0.6534 15 0.12017 0.03103 
Pair 4 IL8 Stimulated  0.9584 15 0.25015 0.06459 
IL8 Stimulated and 
macrolide 0.6765 15 0.11523 0.02975 
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Table 18 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
11.3.2 Chronic Rhinosinusitics 
 
• Baseline IL-6 higher than Normals and AR (p=0.04) 
• Baseline IL-8 higher than Normals and AR (p=0.001) 
• LPS increases IL-6 (p=0.02) however has little effect on IL-8 levels 
(p=0.48) 
• Macrolides increase IL-6 (p=0.001) and IL-8 (p=0.02) in stimulated cells 
• Macrolides decrease IL-6 (p=001)and IL-8 (p-0.001) in unstimulated cells 
 
                                                             
A comparison of the effect of macrolides on stimulated and unstimulated IL-6  
 
and IL-8 in Chronic Rhinosinusitic patients  (pg/µg cellular protein) 
 
Table 19 
 
    Mean N Std Deviation Std Error Mean 
Pair 1 IL6 Unstimulated 0.77 21 0.11 0.025   
  IL6 stimulated 0.91 21 0.18 0.04   
Pair 2 IL8 Unstimulated 1.12 21 0.15 0.03   
  IL8 Stimulated 1.09 21 0.15 0.03   
Pair 3 IL6 stimulated 0.91 21 0.18 0.04   
  IL6 Stimulated and macrolide 1.12 21 0.12 0.03   
Pair 4 IL8 Stimulated 1.1 21 0.15 0.03   
  IL8 Stimulated and macrolide 1.17 21 0.09 0.02   
 
 
Paired Differences 
  Mean 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Sig.(2-
tailed) 
      Lower Upper   
Pair 1 IL6 Pre and 
post 
stimulation -0.5 0.04 -0.6 -0.42 0.001 
Pair 2 IL8 Pre and 
post 
stimulation -0.04 0.06 -0.17 0.1 0.57 
Pair 3 IL6 
Stimulated 
and macrolide  0.42 0.05 0.32 0.52 0.001 
Pair 4 IL8 
Stimulated 
and macrolide 0.28 0.06 0.16 0.41 0.001 
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Table 20 
                      Paired Samples Statistics 
 
 
 
 
                                                                                                                                   
 
 
 
 
 
 
 
The effect of macrolides on baseline IL-6 and IL-8 levels in Chronic  
Rhinosinusitics (pg/µg cellular protein)  
 
 
 
Table 21 
 
  Mean N Std. Deviation 
Std. Error 
Mean 
Pair 1 IL6 
Unstimulated 0.78 21 0.11 0.03
IL6 Macrolide 0.53 21 0.2 0.04
Pair 2 IL8 
Unstimulated 1.12 21 0.15 0.03
IL8 Macrolide 0.91 21 0.16 0.04
 
 
 
 
 
 
 
 
 
 
   Paired Differences 
  Mean 
Std. 
Error 
Mean 
95% Confidence Interval of the 
Difference Sig.(2-tailed) 
      Lower Upper   
Pair 1 IL6 Pre and 
post 
stimulation -0.13 0.052 -0.24 -0.25 0.02
Pair 2 IL8 Pre and 
post 
stimulation 0.03 0.04 -0.06 0.12 0.48
Pair 3 IL6 
Stimulated 
and macrolide  -0.214 0.044 -0.31 -0.12 0.001
Pair 4 IL8 
Stimulated 
and macrolide -0.09 0.03 -0.15 -0.02 0.02
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Table 22 
 
 
    Paired Differences   
    Mean Std. Error Mean 
95% Confidence Interval of 
the Difference 
Sig.(2-
tailed)   
        Lower Upper     
Pair 1 IL6 Unstimulated 0.25 0.45 0.15 0.34 0.001   
  and macrolide           
Pair 2  IL8 Unstimulated 0.21 0.19 0.12 0.29 0.001   
  and macrolides             
 
 
11.3.3 Allergics 
 
• Baseline  IL-6 higher than in Normal (p=0.04) 
• Baseline IL-8 lower than in Allergics (p=0.001) 
• LPS significantly increases IL-6(p=0.02) and IL-8 (p=0.01) levels  
• Macrolides lower IL-6 (p=0.001) and IL-8(p=0.001) levels in stimulated and 
unstimulated  cells 
 
A comparison of the effect of macrolides on stimulated and unstimulated IL-6  
and IL-8 in Allergic Rhinitic patients (pg/µg cellular protein) 
 
  
                                Paired Samples Statistics 
          Table 23 
 
       Mean N 
Std. 
Deviation 
Std. Error 
Mean 
Pair 1 IL6 pre and post-
stimulated 0.66 12 0.12 0.03 
  0.73 12 0.07 0.02 
Pair 2 IL8 pre and post-
stimulated 0.73 12 0.1 0.03 
  1.01 12 0.3 0.08 
Pair 3 IL6 stimulated 
and macrolide 0.73 12 0.07 0.02 
  0.60 12 0.14 0.04 
Pair 4 IL8 stimulated 
and macrolide 1.01 12 0.28 0.08 
  0.68 12 0.1 0.03 
Pair 5 IL6 Unstimulated 
and macrolide 0.66 12 0.12 0.03 
  
0.39 12 0.16 0.05 
Pair 6 IL8 Unstimulated 
and macrolide 0.73 12 0.1 0.03 
  0.5 12 0.12 0.04 
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Table 24 
 
 
                                                            Paired Samples Test 
  
 
      Paired Differences 
      Mean 
Std. Error 
Mean 
95% Confidence Interval of 
the Difference 
Sig.(2-
tailed) 
          Lower Upper   
Pair 
1 IL6 Pre and post stimulation -0.07 0.03 -0.13 -0.01 0.02
              
Pair 
2  IL8 Pre and post stimulation -0.29 0.09 -0.48 0.1 0.01
              
Pair 
3 IL6 Stimulated and macrolide 0.13 0.04 0.26 0.22 0.01
              
Pair 
4 IL8 Stimulated and macrolide 0.33 0.09 0.13 0.54 0.01
              
Pair 
5       
IL6 Unstimulated and 
macrolide 0.27 0.04 0.18 0.35 0.001
              
Pair 
6 
IL8 Unstimulated and 
macrolide 0.23 0.04 0.13 0.33 0.001
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The results are further demonstrated graphically below in Figures 17, 18, 19, 20,  
 
21, 22, 23, 24, 25 & 26 
 
 
                Baseline  IL-6 release from each of the 3 patient groups  
 
 
                
Fig. 17 
                          IL-6 
 
 
 NORMALS      CRS ALLERGIC
GROUP  
0.80 
0.60 
IL6 
95% 
C.I  
Pg/µg
 
 
       p=0.044 
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    Baseline IL-8 release from each of the 3 patient groups  
 
 
 
 
      Fig.18 
 
      IL-8 
 
NORMALS    CRS ALLERGICS
GROUP  
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                P=0.001 
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IL-6 RELEASE IN STIMULATED AND UN-STIMULATED  HNEC’S IN        
                            
THE THREE GROUPS- Pg/µg 
 
 
Fig. 19 
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IL-8 RELEASE IN STIMULATED AND UNSTIMULATED  HNEC’S IN                     
 
THE THREE GROUPS-Pg/ µg 
 
 
Fig.20 
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The effect of 24 hour macrolide exposure on IL-6 release in stimulated      
HNECs of the 3  patient groups  
 
 
 
Fig. 21 
 
 
 
 
  p=0.01   p=0.02     p=0.001 
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The effect of 24 hour macrolide exposure on IL-8 release in stimulated HNECs 
of the 3 patient groups 
 
 
 
 
 
      Fig. 22 
 
 
MACROLIDES STIMULATED 
1.3 
1.2 
1.1 
1.0 
0.9 
0.8 
0.7 
0.6 
IL8 95% 
C.I. 
  MACROLIDES   STIMULATED MACROLIDES   STIMULATED
NORMALS CRSALLERGICS 
 GROUP
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11.4 Summary of results 
 
 
Allergic Rhinitics 
 
Baseline levels of IL-6 in un-stimulated Allergic Rhinitics are significantly higher than in  
 
Normal patients. This indicates a pre-existing increased level of cytokine activity within  
 
nasal epithelium in un-stimulated Allergic Rhinitics. Baseline levels of IL-8, however, are  
 
lowest in Allergics. LPS significantly stimulates this group to increase production of  both  
 
IL-6 and IL-8 LPS significantly raises  IL-6 and IL-8 in AR. Macrolides lower IL-6 and  
 
IL-8 in both stimulated and unstimulated cells.  
 
Chronic Rhinosinusitics 
The results show baseline levels of IL-6 and IL-8 are higher in CRS than AR and Normals. 
This may be explained by increased neutrophilic and eosinophilic activity in CRS as 
opposed to AR. LPS stimulates IL-6 in CRS. LPS significantly raises IL-6 and IL-8 in 
CRS.  
Macrolides increase IL-6 and IL-8 in stimulated cells however reduce levels of both in un-
stimulated cells. These results are observed at 24 hours following exposure to macrolide. 
 
Normals 
Baseline levels of IL-6 and IL-8 are lower in Normals than AR or CRS. LPS significantly 
raised IL-6 however had little effect on IL-8 levels. 
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Macrolides lowered IL-6 and IL-8 in stimulated cells. 
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12. DISCUSSION 
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12. DISCUSSION 
The term ‘rhinitis’ implies inflammation. The symptoms include sneezing, 
irritation, anterior discharge, hyposmia, anosmia and nasal obstruction. Secondary 
symptoms include headache, facial pain, ear popping, nasal obstruction, dry throat, 
post-nasal drip, cough and eye symptoms. It is estimated that morbidity associated 
with nasal symptoms is responsible for over £1.5million caused by loss of working 
hours. The pathophysiology of rhinitis, allergic and non-allergic, is yet to be fully 
understood. The classification of rhinitis is evolving. 
Nasal epithelial cells hold two distinct roles in the inflammatory response. They  
 
enable clearance of particulate matter from the airway and also act as a physical  
 
barrier to the entry of noxious agents. Recent studies have shown that nasal  
 
epithelial cells play a pivotal role in the initiation and control of the inflammatory  
 
process. They are able to release biologically active mediators which modulate the  
 
function of other inflammatory cells implicated in the pathogenesis of rhinitis Pro- 
 
inflammatory cytokines are of particular interest in allergic rhinitis as they  
 
influence the activity of immunocytes such as eosinophils, neutrolphils, T-  
 
lymphocytes and mast cells.  Their presence is a key feature of rhinitis. Studies in 
 
vivo and in vitro have shown that HNECs generate a wide variety of cytokines  
 
including IL1β, TNFα, IL-6, IL-5., IL-8, GM-CSF, RANTES AND MCP-1  
 
(Devalia, Campbell et al. 1993; Kenney, Baker et al. 1994; Davies, Wang et al.  
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1995; Mullol, Xaubet et al. 1995). IL-1β, TNF-α, IL-5 and IL-6 are  
 
multifunctional cytokines synthesized and released by airway epithelial cells. They  
 
all have pro-inflammatory effects on a variety of target cells. 
 
IL6, IL8, TNF-alpha and ICAM-1 have been shown to develop enhanced  
 
expression as a result of bacterial endotoxins. Khair et al in 1995 studied the  
 
effects of erythromycin on the release of IL6, IL8 and sICAM-1 following  
 
haemophilus influenza endotoxin stimulation. Their results showed an increase in   
 
neutrophil chemotaxis within cultured human endothelial cells. The airway 
epithelium is an important barrier between the environment and sub-epithelial 
tissues. The epithelium is functionally divided into apical and basolateral parts. 
The elements of the barrier determine the restriction it provides. The protease-
activated receptor is expressed in airway epithelium and its activation initiates 
multiple effects including enhanced airway inflammation reactivity. 
The effects of protease-activated receptor-2 (PAR-2) stimulation on inflammation 
mechanisms of chronic rhinosinusitis (CRS) are still unknown. Rudack et al 
investigated the expression of PAR-2 receptor expression (Rudack, C., M. 
Steinhoff, et al. (2007). "PAR-2 activation regulates IL-8 and GRO-alpha synthesis 
by NF-kappaB, but not RANTES, IL-6, eotaxin or TARC expression in nasal 
epithelium." Clin Exp Allergy 37(7): 1009-22).  
In primary nasal epithelial cell cultures, the function of PAR-2 and its ability to 
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produce chemokines and IL-6 were measured by calcium mobilization and 
stimulation tests. Inhibition tests were performed using cortisone, serine protease 
inhibitors, cysteine protease inhibitors. Signal transduction pathways were 
analysed by electromobility shift assays (EMSA) and NF-kappa B binding studies. 
The expression of PAR-2 was found to be increased in CRS specimens. The 
activation of PAR by trypsin or PAR-2-specific activating peptide (AP) caused an 
increase in cytosolic calcium, as well as the release of the CXC chemokines IL-8 
and growth-related oncogene (GRO)-alpha, but not the release of CC chemokines 
or IL-6. The study concludes that PAR-2 plays a role in protease-mediated 
regulation - staphylococcal and non-staphylococcal origin - of IL-8 and GRO-alpha 
in nasal epithelial cells, but not in the regulation of CC chemokines. PAR-2 may 
therefore be involved in the pathophysiology of CRS and NP at different sites of 
activation. 
The immunomodulatory apparatus that links both chronic rhinosinusitis and 
allergic rhinitis is complex. An improved understanding of the pathways that are 
involved is necessary to improve management. The ARIA Guidelines published in 
2008 provide an evidence-based guide to the management of allergic rhinitis. The 
European Position Paper on Rhinosinusitis and Nasal Polyps (2007) provides an 
evidence-based management scheme for chronic and acute presentations of the 
condition. 
The fundamentals of this study are based on knowledge of the underlying  
  140 
 
immunomodulatory pathways and factors established in recent years with both  
 
allergic rhinitis and chronic rhinosinusitis. The study aims to identify activity of  
 
specific cytokines, IL-6 and IL-8, both of which contribute to pathways of intra- 
 
cellular activity in each condition. In particular the effects of macrolides on both  
 
allergic rhinitis and chronic rhinosinusitis can further our understanding of the  
 
similarities and differences between the two. 
 
12.1 Culture of HNECs from nasal turbinate biopsy tissue 
12.2 The ‘Devalia’ explant technique for culture of HNECs 
The ‘Devalia’ explant technique was used to grow HNECs for my experiments. 
This technique was originally described by Steele and Arnold in 1985 for tissue 
culture of human bronchial tissue taken from bronchoscopic biopsies (Steele & 
Arnold, 1985). A modified and highly reproducible method was later developed in 
our laboraties at St. Bartholomew’s Hospital by Devalia et al, which has 
subsequently been used for both bronchial and nasal explant cultures (Devalia et al, 
1990). 
Calderon was the first to study HNECs cultures grown using ‘ Devalia’ explant 
technique. He used electron microscopic and immunohistocytochemical evaluation 
to confirm that the cultured cells retained their morphological and histochemical 
characteristics. In addition, light microscopy confirmed normal, synchronous 
ciliary beat frequency (Calderon et al, 1997). These in vitro functional and 
  141 
 
structural characteristics would suggest that ‘Devalia’ nasal explant cultures 
provide a good in-vitro biological model for the study of rhinitis. 
A potential criticism of the ‘Devalia’ explant technique is that contamination of the 
explants with other cell types can occur, particularly fibroblasts. This problem is 
tackled by the employment of a number of precautions- 
a. Avoidance of deep turbinate biopsies which may inadvertently pick up 
submucosal cells. 
b. Careful dissection of each specimen to remove the underlying lamina 
propria. 
c. The use of Falcon Primaria culture dishes, which are coated with a 
fibroblast inhibitor 
d. Light microscopic examination and disposal of contaminated dishes 
12.3 Constitutive cytokine release 
Both in vivo and in vitro studies have demonstrated that HNECs can generate a 
wide variety of cytokines including IL1β, TNFα, IL-5, IL-6, IL-8, GM-CSF, 
RANTES, MCP-1 and sICAM-1 (Devalia et al, 1993a+b; Davies &Devalia, 1992; 
Mullol et al, 1995; Kenney et al, 1994; Marini et al, 1992; Salvi et al, 1999; Mills 
et al, 1999). These cytokines, either directly or in conjunction with one another, 
influence the growth, differentiation, activation, migration and survival or 
inflammatory cells. 
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The two cytokines IL-6 and IL-8 were chosen for the investigation in this study 
because their exact role in the nasal inflammatory process is unclear and because 
these cytokines have been exclusively investigated in previous studies from our 
laboratories, particularly in relation to lower airway inflammation (Khair et al, 
1994; Calderon et al, 1997; Mills et al, 1998a; Rusznak et al, 2000). As outlined 
below IL-6 is released by nasal epithelial cells relatively early in the rhinitic 
process and acts mainly upon the immediate hypersensitivity response; IL-8 is 
involved in the late phase response. 
Interleukin-6 
IL-6 form the group of multi functional cytokines which include  IL1-β, TNFα and 
IL-5 (Borish & Rosenwasser, 1996; Levine, 1995). IL-6 involved in the activation 
of B lymphocytes and facilitates the switching of plasma cells to produce IgE, thus 
sensitising the nasal epithelium. IL-6 is also important in the induction of the acute 
phase response, it produces fever and stimulates hepatocytes to produce acute 
phase proteins such as fibrinogen, C-reactive protein and serum amyloid A (Castell 
et al, 1988; Kishimoto et al, 1992). 
Interleukin-8 
IL-8 is from the group of chemotactic cytokines which include GM-CSF, 
RANTES and MCP-1. Airway epithelial cells have demonstrated to produce large 
amounts of IL-8, which on a molar basis is one of the most potent neutrophil 
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chemo-attractants(Cromwell et al, 1992; Devalia et al, 1993b; Levine, 1995). IL-8 
also induces T lymphocyte and eosinophil chemotaxis as well as activating these 
cells (Baggiolini et al, 1989; Baggiolini, 1992; Borish & Rosenwasser 1996; Shute, 
1994; Warringa et al, 1991). It is noteworthy that IL-8 is an extremely stable 
protein which maintains its biological activity even in the presence of significant 
changes in pH and proteolyitic enzymes, suggesting that once produced it may 
exert a prolonged biological effect (Baggiolini & Clark-Lewis, 1992). 
My results have demonstrated that HNEC explant culture from Normal subjects, 
Chronic Rhinosinusitics and Allergic Rhinitics are capable of constitutive release 
of the cytokines IL-6 and IL-8.  
Kenny et al (Kenny et al, 1994), demonstrated a similar relationship between IL-8 
and IL-6 when they reported constitutive release of cytokines from HNECs as 
follows:- IL-8 > IL-6 > IL-1α > IL-1β  
Similarly Bachert et al (Bachert et al, 1995 a +b), measured cytokine levels in 
nasal lavage fluid and demonstrated the following relationship- IL-8 > IL-6 > 
>TNFα > IL-1β 
Our studies have demonstrated that IL-6 and IL-8 activity exists in all three groups 
of subjects. IL-6 and IL-8 levels are highest in Chronic Rhinosinusitics. Pre-
existing neutrophilic and eosinophilic activity in CRS subjects may explain the 
increased baseline levels of both cytokines. IL-8 levels were lowest in AR.  
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LPS significantly enhanced cytokine activity in all three groups. LPS had little 
effect on IL-8 in Normals. This study reveals inhibitory activity of  Erthromycin in 
stimulated Allergic Rhinitics and Normal subjects with a reduction in levels of IL-
6 and IL-8 seen in both. Stimulated HNEC’s in AR subjects appear to be sensitive 
to an immunomodulatory effect secondary to erythromycin. AR subjects also 
showed sensitivity to erythromycin in un-stimulated HNEC’s.  
The study identifies a significant difference in activity in HNEC’s of CRS subjects. 
An increase in IL-6 and IL-8 levels was identified in stimulated CRS, following 
macrolide exposure, with a contrasting reduction in levels of both IL-6 and IL-8 in 
unstimulated HNEC’s.    
These findings contradict our current understanding behind the principles of  
 
macrolide activity. The complexity of the pathophysiology related to individual   
 
cytokine function is evident. We can stipulate that cytokine activity in CRS, is not  
 
optimally stimulated, and therefore is sensitive to stimulation with LPS. There 
possible explanations for this response are vast. 
 An agonistic response mounted by macrolides can be secondary to  stimulation 
of Protease-Activated Receptors that in-turn upregulate IL-6 and IL-8 activity. LPS 
is known to effect protein expression by IL-8 mRNAS. Macrolides reduce IL-6 and 
IL-8 levels in un-stimulated chronic rhinosinusitis. This indicates an interplay 
between macrolides and that altered cytokine activity is directly related to the 
effects of LPS upon cellular immunomodulation. 
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The results impress the need for further studies to validate these findings. 
Saturation of cytokine activity may prevent enhancement of further activity. The 
study has shown that LPS endotoxin attenuates the release of both inflammatory 
mediators in AR patients and a significant reduction in IL-6 and IL-8 is shown 
with  exposure to macrolides. The reduction can be explained by the theory that 
macrolide reduces LPS endotoxin induced chemotaxis and adhesion to human 
endothelial cells in vitro. This would, in turn, suggest that the effect of LPS 
endotoxin on mediator release from epithelial cells is a specific effect, and that 
erythromycin is likely to interfere with this effect. Whilst it is possible that 
erythromycin may act either to inhibit the expression or the release of these 
inflammatory mediators from human nasal epithelial cells, it is not possible to 
determine which of these two processes is affected from the present studies. In 
order to further investigate the specific mechanism through which erythromycin 
may operate, we require further studies to investigate the effect of erythromycin on 
LPS endotoxin – induced changes in the concentration of specific messenger 
ribonucleic acid transcribed for the mediators investigated in the present study. 
Clinical in-vivo studies have already highlighted the relevance of macrolide in the 
management of chronic rhinosinusitis. Ragab et al have highlighted the long-term 
use of macrolides as a part of a treatment regimen in chronic rhinosinusitis. The 
study found significant improvements in both subjective and objective parameters 
both medical and surgical management of these patients. The aims of this study 
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were to conduct the first prospective, randomised, controlled trial evaluating and 
comparing treatment, both surgical and medical in polypoid and no-polypoid 
chronic rhinosinusitis. A trial of ninety patients concluded a three month  course of 
medical treatment is appropriate prior to considering surgery which should be 
reserved in refractory cases. More relevant to our work the study concluded a three 
month course of macrolides be used in the treatment of moderate to severe chronic 
rhinosinustis. 
In this study a concentration of LPS endotoxin and erythromycin were selected on 
the basis of previous studies which have demonstrated maximal cytokine release 
from epithelial cell cultures. Although clinical effectiveness of erythromycin in the 
management of chronic rhinosinusitis has been suitably established, studies of 
underlying the effects of erythromycin remain wholly unclear. Whilst some studies 
have suggested this drug acts as an antimicrobial others have suggested that it may 
have anti-inflammatory effects. Reviews of the mechanisms underlying the 
antibacterial role of erythromycin and other macrolide antibiotics have 
demonstrated that these agents exhibit their antimicrobial activity by interfering 
with protein synthesis in the microorganism (Brisson-Noel et al). These authors 
suggested that the macrolide antibiotics act primarily by binding reversibly to the 
50 S ribosomal sub-units of sensitive microorganisms, and consequently stimulate 
the dissociation of the peptidyl-transfer ribonucleic acid (tRNA), ribosomes during 
translocation to the mRNA, rather than preventing the peptide bond. 
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This study shows a significant anti-inflammatory effect of erythromycin on allergic 
rhinitics. This has not been previously either studied in vitro or in vivo. It does 
necessitate further investigation to approach the possible role of macrolides in a 
purely anti-inflammatory role. Previous studies have demonstrated the effects of 
erythromycin in different model systems. Iino et al investigated the effect of LPS- 
induced release of TNF-α from human monocytes, and demonstrated that this was 
significantly reduced by treatment with erythromycin. Incubation of LPS-
stimulated monocytes with non-macrolide drugs such as ofloxacin or penicillin G 
did not have any effect on TNF-α release.  Katoda et al investigated the effect of 4 
weeks of treatment with oral erythromycin on neutrophil chemotactic activity 
(NCA) and neutrohil accumulation in bronchoalveolar lavage(BAL) fluid of 
patients with diffuse panbronchiolitis, and demonstrated that these were 
significantly reduced. Anderson et al has suggested that erythromycin may exhibit 
anti-inflammatory effects inhibiting the generation of superoxide by activated 
neutrophils. 
In summary this study suggests erythromycin exhibits anti-inflammatory effects in 
Chronic Rhinosinusitics and stimulated Allergic Rhinitics. It is possible that 
erythromycin could exert its effects by directly inhibiting the activity of 
inflammatory cells in vivo. My study suggests that this agent is more likely to act 
indirectly by modulating the synthesis and/or release of pro-inflammatory 
mediators, such as IL-8 and IL-6 which effect activity of neutrophils, the key 
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effector cell in the pathogenesis of intermittently exacerbated bacterial infections.   
The potential anti-inflammatory effect of macrolides has generated considerable 
interest in the past decade. The effect on mediators of neutrophil inflammation has 
been well defined. In contrast the effect of macrolide on eosinophilic chronic 
rhinosinusitis is still not clear. Macrolides, however, have been in use in the 
management of chronic rhinosinusitis for some years. This study does encourage 
this application. Allergic rhinitis also triggers a systemic increase of inflammatory 
elements. The management of this remains more complex and often poor in 
compliance as patients find little benefit from the recommended medical treatment 
and advice. In addition to causing symptoms of rhinitis, inflammatory cells and 
mediators travel through the circulatory system and are able to target other 
susceptible tissues, leading to exacerbation of co-morbid conditions such as asthma 
and sinusitis.  
Treatment for Allergic Rhinitis needs to be effective long-term. This study 
highlights the need for treatment to be directed at its underlying pathophysiological 
pathway as opposed to simple symptomatic relief. The findings from this are novel 
and encouraging in the progress of further understanding the effects of macrolides 
in a potentially pivotal role. 
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13. FUTURE STUDIES  
 
Epithelial cells are situated, anatomically, in ‘front-line’ and constitute a 
biochemical interface between the cold, dry, polluted external environment and the 
internal milieu. Chronic Rhinosinusitics and Rhinitics are two large groups of 
individuals who suffer from frequent nasal morbidity. In-depth investigation of the 
mechanisms involved in rhinitis would be incomplete without careful study of 
these two groups, however, a search of the world literature reveals that cytokine 
release from HNECs cultured from allergic rhinitis patients and chronic 
rhinosinusitic has never been compared, (from the point of view of constitutive 
cytokine release). Furthermore analyses of in-vivo effects of cytokine release in 
chronic rhinosinusitis have improved our understanding of the mechanism and 
potential management of this condition.  
This study has produced interesting novel data, which has given further insight into  
 
mechanisms involved in the nasal inflammatory response. It has, however,   
 
raised many interesting questions. 
 
Macrolides are effective in significantly reducing IL-6 and IL-8 activity in  
 
stimulated and unstimulated Allergic Rhinitic patients. Cytokine release between 
individuals may be a consequence of inherent differences in the signal transduction 
pathways for specific cytokines. The signalling is part of a complex of pathways 
involving subfamilies of enzymatic proteins such as G- proteins and protein 
kinases.  
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Recent studies have focused on the activity of protease-activated receptors. These 
receptors contribute to the release of pro- and anti- inflammatory mediators. LPS is 
understood to specifically up-regulate expression of PAR-2 but nor PAR-1. 
Activation of  PAR- 2, not PAR-1, appears to influence IL-8 production from 
respiratory epithelial cells. There is significant overlap in the pathways upon which 
agonists specific to these receptors take effect. The in-vitro studies, thus far, have 
focused on pathways within the lower respiratory tract. 60% of asthmatics suffer 
with allergic rhinitis and 20-30% of patients with allergic rhinitis suffer with 
asthma. In normal subjects it is understood that the structure of the airway mucosa 
of the nose and bronchi share similarities. It is understood that inflammation has a 
role in both asthma and rhinitis at a cellular and molecular level. This study should 
act as a springboard for further research in the upper respiratory tract. 
Progress could be made by analysing the effects of agonists upon these receptors 
and thereby the impact on production cytokines such as of IL-8; work that has 
already been carried out on lower respiratory tract epithelium. The impact and 
expression of LPS and agonists on PAR -1 and PAR-2 in allergic rhinitis would 
compare immunomodulatory activity within the lung. The quantitative effect of 
stimulation of these receptors within then nasal epithelium and their impact upon 
sub-groups of interleukins is essential. 
Is the anti-inflammatory effect of macrolides altered by an infective stimulatory  
 
environment? Perhaps cytokines and their susceptibility to anti-inflammatory  
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effects of macrolides is reliant upon an optimal level of activity. Chronic  
 
Rhinosinusitics may provide these ideal conditions.  
 
In-vivo studies are ultimately required to establish the impact and efficacy of 
macrolides as a recognised part of the treatment regimen in Allergic Rhinitis as is 
established in Chronic Rhinosinusitis. These studies would require considerable 
prior, in-vitro, quantitative analyses of the affect of macrolides on this sub-group 
of patients. 
In summary, it would be reasonable to suggest that differences in cytokine release  
 
between individual pathologies result in differences within cytokine formation,  
 
storage and release. The impact of further studies should, over time, relate to  
 
substantive enhancement of knowledge of a condition that remains often very  
 
poorly managed. 
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